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Abstract
Head and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal sinuses, oropharynx, larynx
and nasopharynx represent nearly 700,000 new cases and 380,000 deaths worldwide per annum, and account for
over 10,000 annual deaths in the United States alone. Improvement in outcomes are needed for patients with
recurrent and or metastatic squamous cell carcinoma of the head and neck (HNSCC). In 2016, the US Food and
Drug Administration (FDA) granted the first immunotherapeutic approvals – the anti-PD-1 immune checkpoint
inhibitors nivolumab and pembrolizumab – for the treatment of patients with recurrent squamous cell carcinoma
of the head and neck (HNSCC) that is refractory to platinum-based regimens. The European Commission followed
in 2017 with approval of nivolumab for treatment of the same patient population, and shortly thereafter with
approval of pembrolizumab monotherapy for the treatment of recurrent or metastatic HNSCC in adults whose
tumors express PD-L1 with a ≥ 50% tumor proportion score and have progressed on or after platinum-containing
chemotherapy. Then in 2019, the FDA granted approval for PD-1 inhibition as first-line treatment for patients with
metastatic or unresectable, recurrent HNSCC, approving pembrolizumab in combination with platinum and
fluorouracil for all patients with HNSCC and pembrolizumab as a single agent for patients with HNSCC whose
tumors express a PD-L1 combined positive score ≥ 1. These approvals marked the first new therapies for these
patients since 2006, as well as the first immunotherapeutic approvals in this disease. In light of the introduction of
these novel therapies for the treatment of patients with head and neck cancer, The Society for Immunotherapy of
Cancer (SITC) formed an expert committee tasked with generating consensus recommendations for emerging
immunotherapies, including appropriate patient selection, therapy sequence, response monitoring, adverse event
management, and biomarker testing. These consensus guidelines serve as a foundation to assist clinicians’
understanding of the role of immunotherapies in this disease setting, and to standardize utilization across the field
for patient benefit. Due to country-specific variances in approvals, availability and regulations regarding the
discussed agents, this panel focused solely on FDA-approved drugs for the treatment of patients in the U.S.
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Introduction
Squamous cell carcinoma of the head and neck
(HNSCC) is the 9th leading cancer by incidence world-
wide and constitutes 90% of all head and neck cancers
[1, 2]. In the US, approximately 50,000 new cases of
HNSCC and more than 10,000 deaths occur per year
[3–6]. HNSCC is a biologically diverse and genomically
heterogeneous disease that arises from the squamous
mucosal lining of the upper aerodigestive tract, including
the lip and oral cavity, nasal cavity, paranasal sinuses,
nasopharynx, oropharynx, larynx and hypopharynx [5,
7–10]. In addition to traditional risk factors including
smoking and alcohol consumption, over the last two to
three decades it has become apparent that the human
papillomavirus (HPV) and Epstein Barr Virus (EBV) are
associated with development of squamous cell carcin-
oma of the oropharynx and nasopharynx, respectively
[11–18].
Most patients present with locally advanced disease
with a high risk of recurrence, and approximately 10% of
HNSCC patients present with metastatic disease [19].
Surgical resection of the primary tumor and draining
lymph nodes followed by risk-adapted adjuvant radi-
ation, with or without platinum-based chemotherapy, or
primary definitive concurrent chemoradiation, remain
the principal treatments employed for locally advanced
HNSCC. It is important to note that multimodality
treatment often drastically impacts patient quality of life
(QOL) [20].
Despite advances in surgery and radiotherapy, five-
year survival rates for patients (excluding EBV-related
nasopharyngeal) with HNSCC across all stages remain
40–50% for tumors caused by traditional carcinogens
(HPV-negative). The median overall survival (OS) for
patients with recurrent/metastatic (R/M) disease is 10–
13months [19, 21–25]. The current standard of care
(SOC) for locally recurrent disease (without surgical or
radiation treatment options) and/or metastatic disease in
the first-line setting has been platinum-based doublet
chemotherapy with cetuximab. Compared to chemother-
apy alone, the addition of cetuximab in the regimen de-
scribed extends median progression free survival (PFS)
from 3.3 months to 5.6 months (HR 0.54; P < 0.001), me-
dian OS from 7.4 months to 10.1 months (HR 0.80; P =
0.04), and response rates from 20 to 36% (P < 0.001)
[26]. Furthermore, until recently, second-line treatment
options included only cetuximab, methotrexate, and a
taxane, each of which is associated with response pro-
portions of 10–13%, and median PFS of 2–3 months,
and without clear demonstration of an improvement in
OS [27–30].
In 2016, the US Food and Drug Administration (FDA)
approved two immunotherapeutic agents, the anti-
programmed cell death protein (PD-1) monoclonal
antibodies, nivolumab (Opdivo, Bristol-Myers Squibb) and
pembrolizumab (Keytruda, Merck), for the treatment of pa-
tients with R/M HNSCC refractory to platinum-based ther-
apy. In 2019, the FDA approved pembrolizumab for the
first-line treatment of patients with unresectable R/M
HNSCC. For frontline therapy, pembrolizumab was ap-
proved for use in combination with platinum and fluoro-
uracil for all patients with R/M HNSCC and as a single
agent for patients whose tumors express PD-L1 with a
combined positive score (CPS) ≥1 as determined by an
FDA-approved test. The FDA also expanded the intended
use for the PD-L1 IHC 22C3 pharmDx kit to include use as
a companion diagnostic for selecting patients with HNSCC
for treatment with pembrolizumab as a single agent.
Immunotherapies are designed to enhance immune sys-
tem activity to eradicate cancerous cells [31]. Immune
checkpoint inhibitors (ICIs) are a widely effective class of
immunotherapies that block inhibitory immune check-
point pathways in order to reactivate immune responses
against cancer. Ligation of the PD-1 protein, which can be
expressed by T cells, by PD-L1, often expressed by tumor
cells, results in suppression of T cell immunological re-
sponses and serves as a mechanism of tumor immune
evasion. Anti-PD-1/PD-L1 ICIs can block suppressive sig-
naling through the PD-1/PD-L1 pathway and enhance an-
titumor immune activity [32–34].
There is an urgent need to improve treatment for pa-
tients with recurrent or metastatic squamous cell carcin-
oma of the head and neck (R/M HNSCC). A better
understanding of emerging immunotherapies, including
appropriate patient selection, therapy sequence, response
monitoring, adverse event management, and biomarker
testing, are needed to guide improvements in care. In
order to address these issues, the Society for Immunother-
apy of Cancer (SITC) established the Cancer
Immunotherapy Guideline - Head and Neck Cancer sub-
committee to provide evidence-based recommendations
on how best to incorporate immunotherapies into practice
for the treatment of patients with HNSCC. This panel -
including expert physicians, nurses, scientists, and a pa-
tient advocate - regularly communicated via email, tele-
conference, and in-person between May and November
2018 to refine the utilization and incorporation of data
from available literature and clinical trials into the devel-
opment of an HNSCC-specific consensus management
guideline. These resulting recommendations are meant to
provide guidance to clinicians with the most up-to-date
philosophy on how immunotherapy can be integrated into
the treatment for patients with HNSCC.
Materials and methods
Consensus statement policy
The National Academy of Medicine’s (NAM, formerly
the Institute of Medicine) Standards for Developing
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Trustworthy Clinical Practice Guidelines reported in
March 2011 were used as a model to generate this
consensus statement [35]. In addition, methods applied
previously to SITC consensus guidelines were used to
develop and organize this manuscript [36]. As outlined
by NAM, consensus guideline standards should include
a transparent process for guideline development, funding
sources, and the reporting and management of conflicts
of interest accomplished by a multidisciplinary and bal-
anced committee. Said committee, nominated to estab-
lish an evidence-based foundation for recommendations
and rating system to assess the strength of the evidence,
reports the results through a peer-reviewed publication
and publicly available website, and updates the statement
as required by changes in the field. The subcommittee
should base its recommendations on evidence in the lit-
erature with a rating system to evaluate the strength of
supporting peer-reviewed publications and results from
reported clinical trials. A draft of this consensus statement
was made publicly available for comment between March
15, 2019 and April 14, 2019. All comments were consid-
ered for inclusion into the final manuscript and are avail-
able in supplementary materials (see Additional file 1).
Full consensus recommendations, for this disease as well
as others, can be found on the SITC website [37]. Due to
differences in drug approval, availability and regulations in
some countries, this panel focused solely on FDA-approved
drugs for the treatment of patients in the U.S.
Cancer immunotherapy guideline - head and neck cancer
subcommittee
The Cancer Immunotherapy Guideline - Head and Neck
Cancer subcommittee consisted of 18 participants, including
six medical oncologists, five radiation oncologists, four head
and neck surgical oncologists, one surgical oncologist, one
nurse practitioner, and one patient advocate (see Add-
itional file 2). When polled, 100% of clinical subcommittee
members reported previous experience in using ICIs for the
treatment of patients with HNSCC. The subcommittee con-
vened in May 2018 in accordance with the National Acad-
emy of Medicine and SITC processes to review guideline
development progress as well as results from a previously
distributed questionnaire collecting information on the par-
ticipants’ role in the care of patients with HNSCC. The clin-
ical questionnaire addressed topics related to the role of the
subcommittee members including primary clinical focus, ex-
perience with FDA-approved agents used for immunother-
apy treatments, and current practices in the use or
recommendation for use of such agents.
Consensus panel and conflicts of interest
In accordance with previous SITC practices used in develop-
ment of consensus guidelines, nominated multidisciplinary
subcommittee members were both SITC members and
nonmembers who were expected to be affected by the devel-
opment of clinical guideline recommendations including cli-
nicians, patient representatives, nurses, and others. All
subcommittee members were required to disclose any con-
flicts of interest using a SITC-specific disclosure form, man-
dating disclosure of full financial details and relationships
with commercial entities that could be expected to have dir-
ect regulatory or commercial impact resulting from the pub-
lication of this statement. No commercial funding was
provided to support the consensus subcommittee, literature
review, or the preparation of this manuscript.
Literature review process
The MEDLINE database was used to search the scientific
literature for current therapies related to head and neck can-
cer and immunotherapy in humans. The final search
encompassed articles published from 2012 to 2018 (con-
ducted on December 17, 2018) and was limited to clinical
trials, meta-analyses, practice guidelines, and research in
humans, supplemented by major presentations at inter-
national meetings where abstracts were peer-reviewed. The
search terms included “head and neck neoplasm OR
HNSCC OR SCCHN” and “pembrolizumab”, “nivolumab”,
“durvalumab”, “PD-1,” “PD-L1,” “HPV”, “immunotherapy”,
“immune checkpoint inhibitor”, “PD-1/PD-L1”, “combin-
ation therapy, immunotherapy”, “immunotherapy, bio-
markers”, “adverse event”, and “toxicity”. The search
resulted in retrieval of nearly 200 manuscripts, which were
screened by subcommittee members to include only papers
with clinically accurate and relevant information and to re-
move duplicate articles from independent searches, resulting
in a final bibliography of 157 manuscripts catalogued using
EndNote X7 (see Additional file 3). The bibliography was
supplemented with additional articles identified by the panel,
as appropriate and necessary for a comprehensive literature
review.
Literature was graded into three categories of evidence
which were adapted from the National Comprehensive
Cancer Network (NCCN) guidelines and required con-
sensus among SITC Head and Neck Cancer Guidelines
Subcommittee members. Consensus was defined as
≥75% agreement among subcommittee members. In
short, category 1 is based upon high-level evidence with
consensus among the committee members that the
intervention is appropriate; category 2A is based upon
lower-level evidence where there is uniform consensus
that the intervention is appropriate; category 2B is based
upon lower-level evidence where there is general con-
sensus that the intervention is appropriate; and category
3 is based upon any level of evidence, even where there
is substantial disagreement that the intervention is ap-
propriate. All recommendations are category 2A unless
otherwise noted [38].
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Consensus recommendations
Consistent with current FDA-approved immunother-
apies, the Cancer Immunotherapy Guideline - Head and
Neck Cancer subcommittee generated the following con-
sensus recommendations for management of R/M
HNSCC refractory to platinum-based chemotherapy.
Most of the referenced immunotherapy trials include pa-
tients with Eastern Cooperative Oncology Group
(ECOG) Performance Status (PS) 0 or 1. Additionally,
patients with organ dysfunctions, history of clinically sig-
nificant autoimmune conditions, and other pre-existing
conditions were largely not enrolled into the discussed
trials and extrapolation of clinical recommendations to
these patient populations are outside the purview of this
guideline. Of note, as current immunotherapeutic ap-
provals for the treatment of patients with HNSCC are
relatively novel, few data exist regarding topics such as
combination therapeutic approaches and PD-1 inhibitor
resistance mechanisms. New data will be incorporated
into updated versions of these recommendations as ap-
plicable. A summary table providing high level consen-
sus recommendations (those with level 1 and level 2A
evidence) plus lower evidence, but has more than 50%
subcommittee votes, is provided (Table 1).
KEY CLINICAL QUESTIONS
1. How should immunotherapy with PD-1 inhibitors be
integrated into the treatment of recurrent/metastatic
HNSCC?
Immunotherapies represent a cutting-edge new treat-
ment in HNSCC. ICIs targeting proteins such as PD-1
and PD-L1 have shown promise of durable, long-term
survival in responding HNSCC patients [39–41]. In
2016, backed by the results of two landmark trials
KEYNOTE-012 (NCT01848834) and CheckMate 141
(NCT02105636) – the anti-PD-1 monoclonal antibodies
pembrolizumab and nivolumab became the first im-
munotherapies to gain FDA approval for the treatment
of patients with R/M HNSCC [14, 42–44]. The NCCN
official guidelines list these agents as SOC second line
systemic therapy for R/M HNSCC without a salvage ra-
diation or surgery option [10]. Then in 2019, based on
KEYNOTE-048 (NCT02358031), a randomized, con-
trolled trial conducted in patients with metastatic
HNSCC who had not previously received systemic ther-
apy for metastatic disease or with recurrent disease who
were considered incurable by local therapies, pembroli-
zumab was approved for frontline treatment of patients
with R/M HNSCC (Figs. 1 and 2).
Literature review and analysis
Previously, R/M HNSCC patients in need of second-
line treatment (e.g. fit patients who progress on
platinum-based first-line therapy in the R/M setting)
primarily received either single-agent chemotherapy,
targeted therapy with cetuximab, best supportive care,
or entered into clinical trials [10, 45, 46]. Based on
the phase 1/2 KEYNOTE-012 and phase 3
KEYNOTE-040, and the phase 3 Checkmate 141 clin-
ical trials, pembrolizumab and nivolumab, respect-
ively, have changed the treatment paradigm for
patients with advanced R/M HNSCC (Fig. 2). Import-
antly, while both checkpoint inhibitors are FDA ap-
proved for patients with advanced R/M HNSCC who
have progressed on or after platinum-based chemo-
therapy, neither require PD-L1 expression analysis
prior to treatment except within the EU, where TPS
> 50% is required. KEYNOTE-012 assessed the safety,
tolerability and antitumor activity of pembrolizumab
in an open-label, multicenter, phase 1b trial of pa-
tients with R/M HNSCC. The first 60 patients en-
rolled (cohort B) were required to have evidence of
PD-L1-positive tumors (tumor cells or stroma with
≥1% PD-L1 expression considered PD-L1 positive by
immunohistochemistry [IHC]) and received 10 mg/kg
pembrolizumab intravenously every two weeks. The
remaining 132 enrolled patients were enrolled (cohort
B2) irrespective of tumor PD-L1 expression and re-
ceived pembrolizumab at a fixed dose of 200 mg
intravenously every three weeks [14, 42]. For patients
in cohort B, ORR by central imaging review was 18%
(95% CI, 12 to 26). Per investigator review, the me-
dian duration of response (DOR) was not reached
(range, ≥ 2 to ≥30 months), with 85% of responses
having lasted ≥6 months [14, 42, 47].
Specifically enrolling patients with disease progression
within six months of receiving platinum-based chemo-
therapy, CheckMate 141 was the first reported, random-
ized, phase 3 study of a PD-1 inhibitor in HNSCC, and
enrolled 361 patients regardless of tumor PD-L1 status.
In this trial, patients received either 3 mg/kg nivolumab
every 2 weeks or investigator’s choice of weekly systemic
standard therapy (methotrexate, weekly docetaxel, or
cetuximab). Patients who received nivolumab demon-
strated increased median OS (7.5 months vs. 5.1 months,
respectively) and an increased overall response rate
(ORR; 13.3% vs. 5.8%, respectively) compared to patients
who received chemotherapy. At the first interim analysis,
estimated one-year OS was 36% with nivolumab com-
pared to 16.6% with standard therapy [43]. Furthermore,
only 13.1% of patients treated with nivolumab experi-
enced grade 3/4 TRAEs compared to 35.1% of patients
treated with standard therapy. With 2-year follow-up,
median OS was 7.7 months in patients who received
nivolumab and 5.1 months in those who received
chemotherapy [HR = 0.68 (95% CI, 0.54, 0.86)]. Overall,
two-year CheckMate 141 data demonstrated that nivolu-
mab not only improved OS at the primary analysis, but
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Table 1 Key clinical immunotherapy recommendations for treatment of patients with HNC
Clinical Question Summary recommendation Level of Evidence
(*consensus: >
50%)
1. How should immunotherapy with PD-1 inhibitors be
integrated into the treatment of recurrent/metastatic
HNSCC?
First-line:
• Pembrolizumab is indicated for treatment-naïve R/M HNSCC
○ Pembrolizumab monotherapy may be used to treat patients with
treatment naïve R/M HNSCC and PD-L1 CPS ≥1
○ Pembrolizumab + Chemotherapy (platinum and fluorouracil (FU))
may be used to treat all patients with treatment naïve, biomarker-
unspecified R/M HNSCC patients
* Positivity for PD-L1 as≥ 1 CPS by IHC staining
1
Second-line:
• Pembrolizumab or nivolumab monotherapy should be used to treat
patients with R/M HNSCC who are platinum-refractory, including
those that progressed within six months of platinum-based
chemotherapy
*Alternatively, if a clinical trial is available, this is the preferred option,
especially if biomarker-based, hypothesis-driven
1
2. What is the role of biomarker testing in patients with
HNSCC?
The subcommittee recommends against standard MSI testing Consensus
Positivity for PD-L1 is ≥1% TPS or≥ 1 CPS by IHC staining Consensus
The best use of biomarker testing when treating patients with HNSCC
with immunotherapy is by combined positive score (CPS)
Consensus
3. How does HPV status influence the use of
immunotherapy in HNSCC?
HPV status (based on p16 overexpression) should be included in
treatment planning, but should not influence the decision to treat
patients with R/M HNSCC with SOC immunotherapy
Consensus
4. How should treatment response be evaluated and
managed in patients with advanced HNSCC?
1-month timeframe for initial clinical follow-up for identification of
signs of immune-related symptoms and AEs
Consensus
For continued identification of signs of immune-related symptoms and
AEs, patients to be evaluated at least monthly, and sometimes more
frequently in the setting of active AEs
Consensus
In monitoring patients for signs of response after initial follow-up, pa-
tient evaluation (via radiographic imaging) should occur every three
months
Consensus
If CR or near CR after treatment and six months of maintenance
immunotherapy, continue treatment for at least two years or until
disease progression or toxicity
Consensus
For initial assessment, conduct imaging via CT or PET-CT scan following
a baseline clinical exam of the patient
Consensus
Not acceptable to treat beyond progression if a patient has
symptomatic progression/clinical deterioration
Consensus
If radiographic progression is observed early in treatment, and the
patient is clinically stable, continue treatment until progression is
confirmed on a second scan
Consensus
If disease progression on or after treatment with a PD-1 inhibitor: en-
rollment in a clinical trial, treat with palliative radiotherapy and/or
chemotherapy (a taxane)
Consensus
Anatomical site of the tumor is an important consideration
*potential for airway obstruction, surgical resection or radiotherapy to the
site may alter the course of treatment
Consensus
The term “pseudoprogression” should be avoided in a setting of
worsening symptoms
Consensus
Hyperprogression defined as “a rapid increase in tumor growth rate
(minimum two-fold) compared to the expected or prior growth rate”
Consensus
5. How should immune-related adverse events be rec-
ognized and managed in patients with HNSCC?
*For further detail into toxicity management strategies please refer to the
NCCN Clinical Practice Guidelines in Oncology: Management of
Immunotherapy-Related Toxicities (2019)
Consensus
For an irAE < grade 3, continue ICIs for grade 1 events with the
exception of some neurologic, hematologic or cardiac toxicities. For
grade 2 events, stop IO therapy and provide closely monitored
Consensus
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continued to demonstrate progressively greater benefit
compared to investigator’s choice with minimum 2
years of follow-up, regardless of PD-L1 level of ex-
pression [48].
KEYNOTE-040 further evaluated the efficacy of 2nd
line pembrolizumab in a randomized, phase 3 study. Eli-
gible patients included those with R/M HNSCC after
treatment with platinum-based chemotherapy, with the
exclusion of patients who progressed or relapsed within
3 months on prior platinum therapy. This multicenter,
open-label study compared OS post-treatment with
pembrolizumab to investigator’s choice (IC) of standard
systemic therapy (weekly methotrexate, weekly cetuxi-
mab or Q3W docetaxel). In the intention-to-treat (ITT)
population, irrespective of PD-L1 status, median OS was
8.4 months (95% CI 6.4–9.4) with pembrolizumab versus
Table 1 Key clinical immunotherapy recommendations for treatment of patients with HNC (Continued)
Clinical Question Summary recommendation Level of Evidence
(*consensus: >
50%)
outpatient treatment, including consideration of oral steroids.
For irAE development ≥ grade 3, halt treatment, admitting the patient
to the hospital and administering steroids
Consensus
Routine monitoring of thyroid function, neck and airway through
imaging, and AST/ALT levels
Consensus
In patients that develop hypothyroidism, continue immunotherapy,
providing levothyroxine for management, and evaluating thyroid
function in two-month intervals
Consensus
In the event of bulky disease leading to functional or organ
compromise: halt immunotherapy
Consensus
Pneumonitis is not a greater concern in immunotherapy patients with
HNSCC compared to other cancers
Consensus
6. Are there categories of patients with HNSCC who
should not receive immunotherapy?
Do NOT automatically disqualify patient for anti-PD-1 immunotherapy
based on: age, lung metastases, co-morbidities, auto-immune disease
Consensus
Patients with controlled diseases such as Hepatitis C or are HIV+ with
normal CD4+ T cell counts and who are on antiretroviral therapy are
generally suitable for ICI treatment
Consensus
7. What is the role of immunotherapy in rare head and
neck cancer subtypes?
Cemiplimab should be prescribed for patients with metastatic or
locally-advanced cSCC in the head and neck region who are not candi-
dates for curative surgery or radiation
1
Patients with NPC are distinct from other HNSCC patients. Clinical trial
enrollment is recommended as the primary treatment option for
recurrent and metastatic disease. Where clinical trial enrollment is not
feasible, patients with platinum-refractory NPC may derived clinical
benefit from single-agent PD-1/PD-L1 checkpoint blockade.
Consensus
8. How should immunotherapy be incorporated within
a novel combination systemic therapy strategy for
HNSCC?
Consensus was reached between all clinical members of the
subcommittee to recommend combination therapy (notably
chemotherapy + IO) for rapidly growing disease due to the need for an
enhanced response rate
Consensus
9. Quality of life and Patient Engagement Provide face-to-face counseling with patients and up-to-date literature
to educate patients on how immunotherapy works and its associated
toxicities
Consensus
Meet with patients plus their respective family during office visits to aid
in information retention
Consensus
Treating depression in HNSCC patients with counseling and selective
serotonin reuptake inhibitors (SSRIs)
Consensus
Doctors should pay close attention to depression in general
appointments and should be sure to inquire into and monitor patients’
emotional well-being
Consensus
Clinical trials should be a standard part of a doctor’s discussion with
the patient about their treatment options, especially for patients whose
disease has recurred after first-line therapy
Consensus
*Item of special note
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6.9 months (5.9–8.0) with SOC (hazard ratio 0.80, 0.65–
0.98; p = 0.0161) [44]. Among patients with a combined
positive score (CPS; the number of PD-L1 positive cells
including tumor, lymphocytes and macrophages, in rela-
tion to total tumor cells) for tumor and immune cell
PD-L1-expression of at least 1, median OS was 8.7
months (95% CI 6.9–11.4) with pembrolizumab versus
7.1 months (5·7–8·3) with standard treatments (HR 0.74;
95% CI: 0.58–0.93, p = 0.0070). Among patients with a
CPS score of less than 1, median OS was 6.3 months
(3.9–8.9) with pembrolizumab compared to 7.0 months
(5.1–9.0) with SOC (HR 1.28; 95% CI: 0.8–2.07, p =
0.8476). Furthermore, in patients with PD-L1-expression
in ≥50% of tumor cells (tumor proportion score; TPS >
50%), median OS was 11.6 versus 6.6 months in those
treated with checkpoint inhibition compared to SOC
(HR 0.53; 95% CI 0.35–0.81, p = .0017). Conversely, in
patients with TPS < 50%, median OS was 6.5 versus 7.1
months in those treated with checkpoint inhibition
compared to SOC (HR 0.93; 95% CI 0.73–1.17, p =
0.2675) [44]. Additionally, incidence of grade 3–5
treatment-related adverse events (TRAEs) was signifi-
cantly lower in the pembrolizumab cohort (13.0%) com-
pared to the SOC cohort (36.0%), with 2 and 1%,
respectively, reporting deaths due to TRAEs [44]. Thus,
while pembrolizumab increased median OS compared
with standard chemotherapy irrespective of PD-L1 sta-
tus, the benefit of pembrolizumab was greater in pa-
tients with PD-L1 CPS ≥1 and TPS ≥50% [44].
Anti-PD-1 therapy has recently been approved in the
first line R/M setting. Initial results for the phase 3
KEYNOTE-048 trial (NCT02358031) investigating pem-
brolizumab as 1st line therapy for the treatment of pa-
tients with R/M HNSCC were presented at the 2018
European Society for Medical Oncology (ESMO) Con-
gress [49]. This study randomized 882 patients to receive
treatment in one of three arms: pembrolizumab mono-
therapy, pembrolizumab plus chemotherapy (cisplatin or
Fig. 1 Treatment Algorithm 1: First-line treatment for R/M HNSCC patients. Immunotherapy treatment algorithm for R/M Systemic Therapy Naïve
HNSCC. This treatment strategy takes into account recent data from the Keynote-048 trial and would be reasonable if pembrolizumab is available.
All treatment options shown may be appropriate. The final selection of therapy should be individualized based on patient eligibility and therapy
availability based on the treating physician’s discretion. The goal of these algorithms are to provide advice as the consensus recommendations of
the Subcommittee. 1) Treating physician will determine if patient is fit to undergo pembrolizumab monotherapy or pembrolizumab/cisplatin/5-
FU combination therapy as first-line therapy for R/M HNSCC. 2) If patient experiences disease progression on or after pembrolizumab monotherapy,
patient should receive platinum based chemotherapy or be enrolled in an appropriate clinical trial. 3) If patient experiences disease progression on or
after pembrolizumab/cisplatin/5-FU combination therapy, patient may receive second-line non-platinum based chemotherapy/cetuximab or be
enrolled in an appropriate clinical trial. In addition, patients are eligible for nivolumab or pembrolizumab regardless of PD-L1 expression, according to
the 2016 FDA approvals of nivolumab and pembrolizumab for second-line treatment of patients with HNSCC. *Clinical trials, including those that are
immunotherapy-based, should be considered in all HNSCC patients, in all lines of therapy
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carboplatin and 5-FU) or the EXTREME regimen
(cetuximab plus cisplatin or carboplatin and 5-FU). Eli-
gible patients were not amenable to curative local ther-
apy and had not undergone systemic therapy in the R/M
setting. Chemotherapy was continued for 6 cycles, while
pembrolizumab was continued for up to 24months and
cetuximab indefinitely; in each arm, treatment was dis-
continued in the event of confirmed PD or unacceptable
toxicity [49].
Pembrolizumab monotherapy significantly prolonged
OS in patients with a CPS ≥20 (14.9 vs 10.7 months, re-
spectively; HR 0.61 [95% CI 0.45–0.83]) and in patients
with a CPS ≥1 (12.3 vs 10.3 months, respectively; HR
0.78 [95% CI 0.64–0.96]), and, in all patients irrespective
of CPS, was non-inferior to SOC chemotherapy plus
cetuximab with a non-inferiority boundary of 1.2. Al-
though patients treated with pembrolizumab monother-
apy had a lower ORR compared to patients treated with
SOC (23% vs 36% for CPS ≥20, 19% vs 35% for CPS ≥1),
duration of response (DOR) in patients treated with
pembrolizumab monotherapy was longer compared to
SOC for patients with CPS ≥20 and ≥ 1 (20.9 vs 4.2
months, 20.9 vs 4.5 months, respectively). Overall, treat-
ment with pembrolizumab monotherapy demonstrated a
favorable safety profile with lower incidence of any-
grade, grade 3–4 and grade 5 TRAEs. Moreover, pem-
brolizumab plus platinum-based chemotherapy vs. EX-
TREME significantly prolonged OS in the total patient
population (13.0 vs 10.7 months, respectively; HR 0.77
[95% CI: 0.63–0.93]). There was a similar incidence of
TRAEs and no unexpected toxicity due to addition of
chemotherapy to checkpoint blockade. There were no
differences in PFS between either arms [49].
The KEYNOTE-048 study, which has now changed
SOC therapy for first-line treatment of R/M HNSCC,
showed that although pembrolizumab monotherapy
demonstrated lower response rates, it conferred signifi-
cantly longer OS compared to SOC chemotherapy in
both patients with CPS ≥20 and ≥ 1. Pembrolizumab
monotherapy was non-inferior to the EXTREME
Fig. 2 Treatment Algorithm 2: Second-line treatment for R/M HNSCC patients. Immunotherapy treatment algorithm for platinum-refractory recurrent/metastatic
HNSCC based on current FDA approvals for pembrolizumab and nivolumab as second-line therapies. All treatment options shown may be appropriate. The final
selection of therapy should be individualized based on patient eligibility and therapy availability based on the treating physician’s discretion. The goal of these
algorithms are to provide advice as the consensus recommendations of the Subcommittee. 1) Nivolumab and pembrolizumab have been FDA approved only in
patients with R/M HNSCC and who are refractory to platinum-based chemotherapy. If patient experiences disease progression on or after prior Platinum Based
chemotherapy, patient should receive Immune Checkpoint Inhibitor monotherapy or be enrolled in an appropriate clinic trial. 2) Clinical trials, including those that
are immunotherapy-based, should be considered in all HNSCC patients, in all lines of therapy
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regimen in the total population, employing a non-
inferiority boundary of 1.2.In addition, pembrolizumab
plus chemotherapy improved OS compared to SOC, ir-
respective of PD-L1 status [49]. Updated final analysis of
KEYNOTE-048, presented at ASCO 2019, demonstrated
that the combination of pembrolizumab plus chemother-
apy significantly improved median OS versus EXTREME
in both the CPS ≥20 (14.7 vs. 11.0 months; HR 0.60, 95%
CI 0.45–0.82, P = .0004) and CPS ≥1 (13.6 vs 10.4
months; HR 0.65, 95% CI 0.53–0.80, P < .0001) popula-
tions. Moreover, HR for PFS in patients with CPS ≥20
and CPS ≥1 was 0.76 (0.58–1.01) and 0.84 (0.69–1.02),
respectively, and ORR for patients treated with pembro-
lizumab plus chemotherapy vs. EXTREME was 42.9% vs
38.2% for CPS ≥20 and 36.4% vs 35.7% for CPS ≥1, while
median DOR was 7.1 vs 4.2 months and 6.7 vs 4.3
months, respectively. When tested in the total popula-
tion, pembrolizumab monotherapy did not significantly
improve median OS compared to EXTREME (11.5 vs
10.7 months; HR 0.83, 95% CI 0.70–0.99, p = .0199). In
this group, HR for PFS was 1.29 (1.09–1.53) and ORR
for those treated with pembrolizumab alone vs. EX-
TREME was 16.9% vs 36.0%. Overall, KEYNOTE-048
showed that patients treated with pembrolizumab plus
chemotherapy had superior OS in the PD-L1 CPS
≥20, CPS ≥1, and total populations and those treated
with pembrolizumab alone experienced superior OS
in the CPS ≥20 and ≥ 1 populations, with non-inferior
OS reported for the total population. Such results
support pembrolizumab and pembrolizumab plus
chemotherapy (platinum + 5-FU) as new first-line
SOC options for patients with R/M HNSCC (Fig. 1)
[50]. Additionally, retrospective data suggest that ex-
posure to ICI may increase tumor sensitivity to subse-
quent chemotherapy [51].
Consensus recommendations
Category 1 evidence is provided in data from Checkmate
141 and KEYNOTE-040 for the use of single agent anti-
PD-1 immunotherapy for R/M HNSCC patients with
disease progression after platinum-based chemotherapy.
Checkmate 141 led to full FDA approval of nivolumab
in R/M HNSCC patients (for patients not amenable to
salvage therapy) with disease progression on or after
platinum-based chemotherapy if their tumor progressed
after receipt of platinum-based chemotherapy adminis-
tered in the neoadjuvant, concurrent or adjuvant setting
as part of primary therapy for their cancer or as first-line
therapy for recurrent or metastatic HNSCC. Prescribing
dose information is listed as a fixed-dose of 240 mg
every 2 weeks (Q2W) or a fixed-dose of 480 mgs Q4W.
Based on results of KEYNOTE-012, the FDA granted
accelerated approval of pembrolizumab in platinum-
refractory R/M HNSCC patients. As a condition of this
accelerated approval, the randomized, phase 3
KEYNOTE-040 trial was conducted in patients with R/
M HNSCC with disease progression on or after
platinum-containing chemotherapy with a primary OS
endpoint [52]. Prescribing dose information for pembro-
lizumab is listed as 200 mg every 3 weeks (Q3W).
Category 1 evidence is also provided in data from
KEYNOTE-048 for use of pembrolizumab anti-PD-1
therapy in patients with R/M HNSCC who have not re-
ceived prior treatment with platinum-based chemother-
apy for R/M disease. Category 1 evidence from
KEYNOTE-048 showed both significantly improved OS
for patients with R/M HNSCC with PD-L1 CPS ≥20
and ≥ 1 upon treatment with pembrolizumab monother-
apy (200 mg Q3W) as well as for biomarker-unspecified
R/M HNSCC patients upon treatment with pembrolizu-
mab (200 mg Q3W) + chemotherapy (cisplatin 100mg/
m2 or carboplatin AUC 5 Q3W+ 5-FU 1000mg/m2/d
for 4 d Q3W).
The remaining consensus recommendations in this section
are derived from experience-based standards of practice
The majority of the subcommittee recommended treat-
ment with anti-PD-1 monotherapy (82%) for R/M
HNSCC patients who are platinum-refractory including
those who progressed within six months of platinum-
based chemotherapy. Alternatively, if a clinical trial is
available, the majority (94%) found this to be the pre-
ferred option, especially if it is a biomarker-based,
hypothesis-driven clinical trial (59%).
For R/M, platinum-refractory patients with good per-
formance status (ECOG PS = 0/1) the subcommittee rec-
ommends enrollment in a clinical trial as their first
treatment choice followed by treatment with anti-PD-1
monotherapy as second choice, and radiotherapy,
chemotherapy, or EGFR targeted therapy as third choice.
For R/M, platinum-refractory patients with poor per-
formance status (ECOG PS = 2) the subcommittee rec-
ommends anti-PD-1 monotherapy as their first choice of
treatment, EGFR targeted therapy as second choice, and
radio and/or chemotherapy as third choice. The com-
mittee noted several factors that may affect clinical deci-
sion making with respect to use of single agent PD-1
therapy for platinum-refractory R/M HNSCC. In the
setting of rapidly growing disease, 59% recommended
treatment with cytotoxic chemotherapy. For these
patients, docetaxel was chosen more frequently than
methotrexate, paclitaxel or carboplatin-5FU, or cetuxi-
mab. In appropriate patients who progress on IO mono-
therapy, cetuximab + platinum-based therapy may still
be offered as a treatment alternative for fit patients in
the second-line setting. We note that there is no pro-
spective evidence to support the use of ICI in
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combination with cytotoxic chemotherapy in the
platinum-refractory setting.
2. What is the role of biomarker testing in patients with
HNSCC?
Both nivolumab and pembrolizumab are approved for
the treatment of patients with R/M HNSCC with disease
progression on or after platinum-based therapy, without
the requirement for biomarker testing. However, the ma-
jority of HNSCC patients will progress on these agents,
highlighting the importance of developing predictive
biomarkers to better determine who will benefit from
treatment with anti-PD-1/PD-L1 ICIs. Specific prognos-
tic biomarkers that have been evaluated in HNSCC in-
clude programmed death ligand 1 (PD-L1) expression,
tumor mutational burden (TMB), and immune gene sig-
natures within both the tumor and the surrounding tis-
sue [11–18]. With demonstrated evidence that PD-L1
positivity enriches for populations with clinical benefit,
the greatest emphasis thus far, has been placed on PD-L1
expression in the tumor and various immune cells. How-
ever, identification of other predictive biomarkers is
needed to improve response in larger patient populations.
Literature review and analysis
PD-L1 expression PD-L1 expression has been extensively
analyzed as a biomarker and has shown moderate predict-
ive value across multiple solid tumors [53]. Specifically, in
HNSCC a number of trials have evaluated PD-L1 expres-
sion by IHC on tumor cells alone or in combination with
PD-L1 expression on tumor-infiltrating immune and stro-
mal cells. In Checkmate 141, tumor cell PD-L1 membrane
expression was analyzed (Dako PD-L1 IHC 28–8 pharmDx
test), with > 1% expression considered positive. Analysis
showed a greater reduction in the risk of death with nivolu-
mab versus standard therapy in patients with PD-L1 posi-
tive tumors (HR for death: 0.55; 95% CI: 0.36–0.83)
compared to those who with PD-L1 negative tumors (HR
for death: 0.89; 95% CI: 0.54–1.45). While the benefit for
patients with PD-L1 positive tumors was maintained, over
time the magnitude of benefit of nivolumab compared to
SOC increased in patients with PD-L1 negative tumors,
with a decrease in the HR for death to 0.73 (95% CI: 0.49–
1.09) at two-years of follow up [43, 48]. With increased
tumor PD-L1 expression (> 1% vs. > 5% vs. > 10%), nivolu-
mab increased ORR but did not impact OS [43].
In KEYNOTE-040, > 50% TPS (Dako PD-L1 IHC
22C3 pharmDx) was associated with an ORR of 26.6%
and a significant increase in OS and PFS compared to
SOC [44]. Furthermore in 62 patients with R/M HNSCC
treated with anti-PD-L1 durvalumab on a phase I/II
study, ORR was 18% in patients with high PD-L1
expression (tumor cell ≥25%, Ventana PD-L1 (SP263)
assay) compared to 8% in patients with tumor cell PD-
L1–low/negative expression (tumor cell < 25%) [54, 55].
PD-L1 expression by tumor-infiltrating immune cells
has also been associated with increased predictive value,
beyond tumor cell PD-L1 expression alone, in HNSCC.
A retrospective analysis of patients in KEYNOTE-012
showed no statistically-significant difference in ORR be-
tween PD-L1 positive and PD-L1 negative tumors (19%
vs. 16%, respectively; p = 0.35), using TPS > 1% for defin-
ing positivity; however, when CPS was used, patients
with PD-L1 positive tumors had a significant increase in
ORR (22% vs. 4%, respectively; p = 0.021) as well as PFS
and OS with treatment with pembrolizumab [42]. Fac-
toring both tumor cells and immune cells, KEYNOTE-
040 patients with a combined positive score (CPS) > 1
showed a significant improvement in OS compared to
SOC (one-year OS 40.1% vs. 26.1%; HR: 0.74 (95% CI:
0.58–0.93), p = 0.0049) [44]. In CheckMate 141, the pres-
ence of PD-L1 expressing tumor-associated immune
cells was more predictive of benefit than tumor cell PD-
L1 expression alone [56]. While the inclusion of these
immune cells predicted increased benefit from nivolu-
mab compared to SOC for both tumor PD-L1 positive
and negative patients, the enhanced predictive value was
greater in tumor cell PD-L1 negative patients [57]. The
inclusion of PD-L2 expression by tumor and immune
cells in addition to PD-L1 was also associated with in-
creased response rate with pembrolizumab [58].
KEYNOTE-048 showed that compared with SOC
chemotherapy (platinum + 5-FU), pembrolizumab plus
chemotherapy demonstrated superior OS in the PD-L1
CPS ≥20, CPS ≥1, and total populations and pembrolizu-
mab monotherapy demonstrated superior OS in the CPS
≥20 and ≥ 1 populations and was non-inferior in the
total population [50].
Tumor PD-L1 expression generally correlates with im-
proved efficacy with anti-PD-1/PD-L1 ICIs in R/M
HNSCC, with increased predictive value when including
PD-L1 expression on tumor infiltrating immune cells.
The predictive value of PD-L1 expression is not abso-
lute, however, and some patients who are PD-L1 nega-
tive still benefit from treatment with these agents. It
should be noted that with the exception of data from
KEYNOTE-048, most data available represent explora-
tory retrospective analysis of prospective trials. Chal-
lenges to using PD-L1 as a biomarker in R/M HNSCC
include intra- and inter-tumor heterogeneity. As well,
comparisons between trials are limited by differences in
cut points used to define “positive” and differences in
methodology (tumor cell alone versus tumor cell and
immune cell). Regarding assays used for PD-L1 testing,
the Dako PD-L1 IHC 28–8 pharmDx test, Dako PD-L1
IHC 22C3 pharmDx, and Ventana PD-L1 IHC SP263
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were used in previously discussed trials with nivolumab,
pembrolizumab, and durvalumab, respectively. In a com-
parative study performed on 108 tumor biopsy samples
from stage I–IV HNSCC patients, results were assessed
using 3 PD-L1 diagnostic assays: the Ventana SP263, the
Dako 28–8, and Dako 22C3 assays, commonly used in
durvalumab, nivolumab and pembrolizumab trials, re-
spectively. In line with the recent first-line approval,
FDA also expanded the intended use for the PD-L1 IHC
22C3 pharmDx kit to include use as a companion diag-
nostic device to select patients with HNSCC for treat-
ment with pembrolizumab as a single agent. Assays were
performed in an accredited laboratory and followed the
protocol provided by each device. Congruity between
tumor membrane staining was assessed across a range of
clinically relevant cut offs (≥1%, ≥10% and ≥ 25%). Lower
95% CI were calculated using the Clopper-Pearson
method. Results demonstrated that reported data from
each machine had strong associations, with a Spearman
correlation coefficient of ≥0.9 for each pairwise compari-
son. Between the three assays there was an overall agree-
ment of > 90% [59]. In non-small cell lung cancer
(NSCLC), high concordance with tumor cell PD-L1 ex-
pression was seen when comparing these three assays
(lower tumor cell PD-L1 expression was observed with
the Ventana SP142 assay comparatively); however, con-
cordance between these assays was lower for immune
cell PD-L1 expression [60].
Immune gene expression and tumor mutational burden
Additional predictive biomarkers for immunotherapy
strive to characterize the functional state of immune
cells in the tumor microenvironment. Towards this goal,
immune gene expression profile (GEP) scores via ana-
lysis of extracted RNA, characterize the “T cell activation
status” in the tumor microenvironment, and have been
observed to predict anti-PD-1 efficacy across various
tumor types, including HNSCC [14, 61–64]. A compos-
ite score based on interferon gamma and five interferon
gamma-related genes (CXCL9, CXCL10, IDO1, HLA-
DRA, and STAT1) significantly correlated with response
rate as well as PFS in patients with R/M HNSCC treated
with pembrolizumab in KEYNOTE-012. Specifically, pa-
tients with a score above the Youden index - a measure
of the effectiveness of a diagnostic test [65] - displayed
ORR of 40% compared to 5% for those who scored
below the index (95% negative predictive value) [14].
Furthering these results, in a cohort of 258 patients with
R/M HNSCC treated with pembrolizumab in
KEYNOTE-012 and -055, a high GEP score based on 18
genes was significantly and independently associated
with increased response, PFS, and OS [66]. High tumor
mutational burden (TMB), which has been associated
with better efficacy with treatment with ICIs in
numerous solid tumors [67–69], was predictive of re-
sponse and PFS but not OS in this analysis. Importantly,
the predictive value of GEP and TMB were each inde-
pendently associated with response, and responses were
highest in patients that had both high GEP and TMB
[66].
Consensus recommendations
KEYNOTE-048 provided category 1 evidence for PD-L1
expression analysis by CPS ≥20 and ≥ 1, showing im-
proved overall survival for such patients upon treatment
with pembrolizumab monotherapy. The subsequent
approval of pembrolizumab for use as a single agent for
patients whose tumors express PD-L1 CPS ≥ 1 marks the
first mandated biomarker testing of patients with R/M
HNSCC tumors.
Ninety-four percent of the subcommittee defined posi-
tivity for PD-L1 as ≥1% TPS or ≥ 1 CPS by IHC staining.
However, it is important to note that expression levels
may differ depending on the antibody used and whether
staining includes tumor alone (TPS) or tumor plus
stroma (CPS). The majority of the subcommittee (81%)
also agreed that the best use of biomarker testing when
treating patients with HNSCC with immunotherapy is
by combined positive score (CPS). The remaining 3 sub-
committee members did not recommend any specific
form of biomarker testing for patients with R/M
HNSCC prior to administration of approved immuno-
therapies since no testing is currently recommended or
required by the FDA (pending FDA approvals for treat-
ment related to KN-048 data). One such subcommittee
member noted that CPS has more predictive value in
retrospective analysis and will become the biomarker of
choice when pembrolizumab monotherapy is approved
by the FDA.
While pembrolizumab received FDA approval in 2017
for the treatment of adult and pediatric patients with
unresectable or metastatic solid tumors that have been
identified as being microsatellite instability-high (MSI-
H) [70], the frequency of MSI-H HNSCC tumors is rela-
tively low, at about 1–3% [71, 72]. Given the low rate of
MSI incidence in HNSCC, the subcommittee (88%) rec-
ommended against standard MSI testing, unless the pa-
tient is having a genome profile performed already
which will provide such information. TMB analysis is
not currently recommended by the FDA in HNSCC.
3. How does HPV status influence the use of
immunotherapy in HNSCC?
Approximately 25% of all HNSCCs worldwide are
thought to be related to human papillomavirus (HPV)
infection [73]; these cancers are predominantly found in
the oropharynx, and are clinically and biologically dis-
tinct from their non-viral related counterparts. HPV-
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related (HPV+) HNSCC is associated with a relatively fa-
vorable prognosis, > 90% locoregional control with con-
ventional therapies, and a distant metastasis rate of
approximately 8–10%. The subcommittee discussed
whether patient HPV status should influence immuno-
therapy recommendations.
Literature review and analysis
In KEYNOTE-012, patients were required to provide tis-
sue tumor biopsy samples for analysis [14]. Patients were
classified as having HPV+ disease if the primary location
of their tumor was in the oropharynx and at least 70% of
cells stained moderately or strongly positive for p16 by
IHC [47]. Of the patients in the head and neck cohorts,
the percentage of HPV+ patients was relatively small
with 45 (23%) being HPV+ and 147 (77%) being HPV-
[74]. When stratified by HPV status, response rates were
higher in HPV+ patients compared to HPV- patients,
with demonstrated ORRs of 24% (95% CI, 13–40%)and
16% (95% CI, 10–23), respectively [14, 47]. Response
duration ranging above 60 weeks was observed among
both HPV+ and HPV- patients [14]. For patients en-
rolled in KEYNOTE-012 irrespective of PD-L1 status,
ORR was 32% (9/28 patients) and 14% (15/104 patients)
among patients with HPV+ and HPV- disease, respect-
ively [42].
Furthermore, the phase II HAWK trial examined the
efficacy of durvalumab monotherapy vs. SOC chemo-
therapy in immunotherapy-naïve patients with R/M
HNSCC with high tumor PD-L1 expression. In an ex-
ploratory analysis by HPV status, patients with HPV-
positive oropharyngeal squamous cell carcinoma demon-
strated an ORR of 30%, compared with 10.8% in those
who were HPV- [54].
Patients enrolled in the CheckMate 141 study were an-
alyzed post-hoc by HPV status as determined by p16
staining. Here, 63 (26%) patients were HPV+, 50 (21%)
were HPV-, 127 (53%) were not tested [75]. Analyses re-
vealed a benefit with nivolumab compared to SOC
chemotherapy, irrespective of HPV status (HPV- pa-
tients, HR 0.73, 95% CI: 0.42–1.25; HPV+ patients, HR
0.56, 95% CI 0.32–0.99) [43]. A recent update confirmed
a consistent benefit of nivolumab compared to SOC
across both HPV+ and HPV- patients (HPV- patients,
HR 0.59, 95% CI: 0.38–0.92; HPV+ patients, HR 0.60,
95% CI: 0.37–0.97) [48].
Consensus recommendations
Overall, HPV status should not affect selection of pa-
tients with platinum-refractory R/M HNSCC for ICI
therapy. Specifically, while 55.5% of the subcommittee
stated that HPV status (based on p16 overexpression)
should be included in treatment planning, 83% voted
that it does not influence their decision to treat patients
with R/M HNSCC with SOC immunotherapy. For their
reasoning, the subcommittee noted a lack of strong data
suggesting p16+ patients experience a distinct benefit
and that data thus far indicate that both p16+ and p16-
populations benefit from available checkpoint inhibitors.
4. How should treatment response be evaluated and
managed in patients with advanced HNSCC?
Vigilant patient evaluation, monitoring and management
strategies are crucial when administering immunother-
apies. A significant question facing the field of cancer
immunotherapy is how to evaluate therapeutic response
given that the kinetics of patient response to immuno-
therapy may be different than with cytotoxic chemother-
apy. For instance, patients receiving checkpoint
inhibitors may have stable disease for many months be-
fore experiencing a radiographic objective response,
whereas this phenomenon is not generally seen in pa-
tients undergoing chemotherapy or targeted therapies.
Clinicians should be aware that kinetics of ICI response
may vary by patient and by agent/combination, and the
clinician should be aware of rapid/hyperprogression,
prolonged stable disease, and even delayed response or
new lesions, all of which should be monitored appropri-
ately. Important questions include: Whether to choose
ORR, PFS, or OS as optimal metrics with which to
evaluate the clinical benefit of immunotherapy, how best
to use radiographic response criteria such as RECIST,
and the best time interval for imaging evaluation of IO
efficacy to prevent premature withdrawal of a potentially
effective therapy. There are also many management con-
siderations, including biomarker testing prior to im-
munotherapy administration, when to halt or delay
treatment in the event of an irAE, and for how long to
continue treatment.
Two immunotherapy-related paradigms are pseudo-
progression and hyperprogression. Pseudo-progression,
defined as an initial flare-up of lesion diameter on im-
aging perhaps due to inflammation (potentially suggest-
ive of tumor progression) followed by tumor shrinkage,
is considered a rare, but possible, event in solid tumors
[76, 77]. Hyperprogression, on the other hand, occurs
when there is a very rapid tumor progression following
immunotherapy, suggesting that the therapy may have
negatively affected certain patients [77–79]. As such,
new methods of disease evaluation and surveillance have
been developed, including immunotherapy-centric re-
sponse metrics, such as the immune-related response
criteria (irRC) and immune-related Response Evaluation
Criteria in Solid Tumors (irRECIST) [77, 80]. The con-
cern is that conventional response criteria such as
RECIST v1.1 may underestimate the therapeutic benefit
of ICIs due to an occurrence of objective response and
prolonged disease stabilization after the initial
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appearance of tumor flare. Here, irRC were developed to
provide a more detailed observation of the atypical re-
sponse patterns observed in checkpoint blockade. Key
differences between immune-based response criteria and
RECIST v1.1 focuses on initial evaluation of disease pro-
gression which accounts for delayed response and tumor
flare through standardized imaging for up to 12 weeks
post-treatment. For instance, under RECIST v1.1, the ap-
pearance of new lesions or an increase in tumor burden
would always equate to PD. However, irRC and irRE-
CIST require confirmation of initial evidence of progres-
sive disease and new lesions may be added to the total
tumor burden instead of being labeled PD. Under irRE-
CIST, if tumor flare is followed by tumor shrinkage on a
subsequent checkup, the bar is reset and the flare would
be considered immune unconfirmed progressive disease
[77, 81–86]. Such details have proven important in the
evaluation and management of checkpoint blockade
therapy because an inaccurate interpretation of response
can result in premature termination of therapy and pre-
mature removal of said patient from a trial. Based on
these considerations, the subcommittee discussed
optimization of response criteria for patients with R/M
HNSCC treated with immunotherapies and worked to
determine a consensus recommendation concerning
HNSCC patient evaluation and management.
Literature review and analysis
Patients enrolled in the CheckMate 141 trial were
treated until disease progression or an unacceptable level
of toxicity occurred [43]. Patients were evaluated for re-
sponse using the RECIST 1.1 criteria every six weeks
starting nine weeks post-treatment initiation. Check-
Mate 141 described clinical outcomes by best OR for the
anti-PD-1 and the SOC arms. The trial was stopped
early due to a survival advantage for patients treated in
the experimental arm with a statistically significant haz-
ard ratio of 0.70 [43]. A report from the AACR 2017 an-
nual meeting found that some patients treated beyond
progression with nivolumab demonstrated clinical bene-
fit. In this study, 139 of 240 patients (58%) randomized
to nivolumab experienced disease progression according
to RECIST v1.1 definitions. Among those who experi-
enced PD, 41% were treated beyond progression for a
mean duration of 2.0 months. Median OS was 12.7
months in this group (95% CI 9.7, NR). Moreover, after
initial progression, 23% of patients treated beyond pro-
gression experienced a reduction in target lesion size, in-
cluding 2 patients (5%) with over 30% reduction in
tumor size [87].
During KEYNOTE-012 and KEYNOTE-040, pembroli-
zumab was administered for 24 months or until disease
progression, unacceptable toxicity or investigator deci-
sion to halt treatment. In KEYNOTE-040, imaging
occurred using RECIST v1.1 first at nine weeks and then
every six weeks following. Modified RECIST methods
were also used to account for distinct responses due to
treatment with pembrolizumab. This version of RECIST
allowed for continued treatment after initial radiographic
progression until confirmation imaging at least four
weeks later. PD in this trial was defined as ≥20% increase
in the sum of diameters of target lesions and had to
demonstrate an absolute increase of ≥5 mm. The appear-
ance of at least one new lesion was also considered pro-
gression. Radiographic responses were analyzed in real
time for confirmation of PD by RECIST v1.1. Survival
follow-up occurred every 12 weeks [44]. Of note, Check-
Mate 153 assessed patients with advanced NSCLC who
completed 1 year of nivolumab therapy and were subse-
quently randomized to continuous nivolumab or to stop-
ping nivolumab, with the option to reinitiate therapy in
the case of disease progression. This trial reported that
continuous treatment with nivolumab until PD was
associated with superior PFS compared with a 1-year
fixed duration treatment (hazard ratio [HR], 0.43; 95%
CI, 0.25–0.76) [88].
Moreover, data from R/M HNSCC patients treated in
four French centers (Antoine Lacassagne Center, Nice;
Léon Bérard Center, Lyon; Curie Institute, Paris; Gustave
Roussy, Villejuif ) between September 2012 and Septem-
ber 2015 were retrospectively collected to investigate
tumor growth kinetics post-treatment with PD-1/PD-L1
inhibitors. Among the 64 R/M HNSCC patients identi-
fied, 34 were eligible for analysis. Images for pre-baseline
and during immunotherapy analysis were retrospectively
reviewed to assess the ORR and the PFS according to
RECIST 1.1 and irRECIST. Patterns of recurrence in-
cluded loco-regional recurrence in 14 patients, distant
metastases in 11 patients, and occurrence of both in 9
patients. Hyperprogression was observed in ten patients
(29%) total, including 9/23 patients with at least a loco-
regional recurrence and only 1/11 patients with exclu-
sively distant metastases. Hyperprogression was signifi-
cantly correlated with a shorter PFS according to
RECIST (P = 0.003) and irRECIST (P = 0.02), but not
with OS (P = 0.77). No pseudo-progression events were
reported [79]. Additionally, 1 out of 104 patients re-
cruited to the KEYNOTE-012 trial was reported to have
pseudoprogression [14].
Consensus recommendations
While category 1 evidence does not exist here, all studies
demonstrating efficacy of anti-PD1 have used RECIST
v1.1 and this version continues to be used in most
current immunotherapy clinical trials [89].
The subcommittee was split in their recommendation
of RECIST (56%) versus irRECIST (44%) to assess re-
sponse in patients with HNSCC being treated with
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immunotherapy. Moreover, the correct timeframe and
interval for patient monitoring during and after im-
munotherapy treatment is not completely understood.
Such monitoring is crucial to promptly identify and
manage signs of progression, symptoms and adverse
events. 53% of the subcommittee recommends a one-
month timeframe for initial clinical follow-up for identi-
fication of signs of immune-related symptoms and AEs.
For continued identification of signs of immune-related
symptoms and AEs, the subcommittee recommends pa-
tients to be evaluated at least monthly, and sometimes
more frequently in the setting of active AEs (71%). In
monitoring patients for signs of response after initial
follow-up, the majority of the subcommittee (65%) rec-
ommends patient evaluation (via radiographic imaging)
every three months with SOC imaging to be adapted to
patient disease status, response, and tolerability of the
regimen.
In determining duration of treatment in the case of a
patient experiencing a CR or near CR after treatment
with anti-PD1 therapy, 53% of the subcommittee recom-
mend continuing treatment for at least two years (up to
indefinitely) or until the patient experiences disease pro-
gression or toxicity. Only 20% of the subcommittee rec-
ommended stopping immunotherapy at this point and
monitoring until progression. For patients with HNSCC
who enter disease remission on immunotherapy, the
subcommittee was split on continuing treatment for a
total duration of one (40%) or two years (40%) given no
disease progression or toxicity.
Regarding efficacy metrics, the subcommittee unani-
mously agreed that describing study outcomes in terms
of ORR and OS benefit after treatment with checkpoint
blockade therapy in patients with HNSCC is sufficient
for future therapeutic consideration. Forty-one percent
of the subcommittee further clarified their responses by
noting that they would favor OS over ORR. For initial
assessment, the subcommittee recommends using either
a CT (53%) or PET-CT (41%) scan following a baseline
clinical exam of the patient. To best capture the dynam-
ics of changing tumor size, the subcommittee recom-
mends imaging, particularly utilizing a CT scan (44%).
Furthermore, the subcommittee (88%) agreed that it is
not acceptable to treat beyond progression if a patient
has symptomatic progression/clinical deterioration. In
the event radiographic progression is observed early in
treatment, and the patient is clinically stable, the major-
ity of the subcommittee (76%) recommends continuing
immunotherapy treatment until progression is con-
firmed on a second scan. Of note, subcommittee mem-
bers stated that this recommendation to continue
immunotherapy until a second scan confirms progres-
sion may be modified depending on clinical trial options
available for 2nd or 3rd line treatment as well as the
specific characteristics and kinetics of the patient’s dis-
ease such as PD-L1 expression, prior therapies, disease
burden, or rapid progression with high symptom burden.
As for treating patients with HNSCC with disease pro-
gression on or after treatment with a PD-1 inhibitor,
81% of the subcommittee recommended enrollment in a
clinical trial and 78% recommended treating with pallia-
tive radiotherapy and/or chemotherapy. Of those who
recommended chemotherapy, 57% specifically recom-
mended treatment with a taxane.
With respect to tumor characteristics influencing
treatment, 56% of the subcommittee agreed that ana-
tomical site of the tumor is an important consideration.
For instance, potential for airway obstruction, surgical
resection or radiotherapy to the site may alter the course
of treatment. Similarly, the committee was split (44%
versus 44%, with 12% undecided) regarding the notion
that patients with bulkier tumors were less likely to re-
spond to immunotherapy.
As noted above, cancer treatment-response kinetics
observed in immunotherapy patients may differ from
those in patients treated with chemotherapy, radiother-
apy, surgery and targeted therapies. This unique re-
sponse can be seen in patients after checkpoint blockade
in a number of ways, including pseudoprogression,
hyperprogression, and delayed response. 94.1% of the
subcommittee agreed that the term “pseudoprogression”
should be avoided in a setting of worsening symptoms.
70.6% of the subcommittee recommended defining
hyperprogression as “a rapid increase in tumor growth
rate (minimum two-fold) compared to the expected
growth rate.” Alternatively, other accepted definitions of
hyperprogression found in the literature include: a
“RECIST progression at the first evaluation and as a ≥2-
fold increase of the tumor growth rate between the ref-
erence and the experimental periods” [90], “time-to-
treatment failure (TTF) < two months, >50% increase in
tumor burden compared to pre-immunotherapy im-
aging, and >two-fold increase in progression pace” [91],
“a tumor growth kinetics ratio equal to or greater than
two” [79].
5. How should immune-related adverse events be
recognized and managed in patients with HNSCC?
Patients treated with immunotherapy have demonstrated
specific side effects known as immune-related adverse
events (irAEs). Overall, anti-PD-1 drugs are less toxic
than standard chemotherapy [92–98], but irAEs are con-
sistently reported in clinical trials. Immune-related ad-
verse events can affect any organ system including
manifestations as colitis, pneumonitis, endocrinopathies,
or hepatitis, for example [14, 43, 92, 93, 95]. Additional
management considerations in patients with HNSCC in-
clude complications such as potential bleeding, including
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carotid artery rupture, airway compromise due to tumor
bulk, and facial edema [99, 100]. The subcommittee dis-
cussed irAE management strategies in patients with R/M
HNSCC.
Literature review and analysis
In CheckMate 141, toxicities were assessed using the
National Cancer Institute Common Terminology Cri-
teria for Adverse events (NCI CTCAE) version 4.0
throughout the study and treatment was discontinued
when appropriate [43]. The long-term follow-up con-
ducted by this study demonstrates the lasting effects and
safety profile of nivolumab regardless of PD-L1 status.
AEs were measured at each treatment visit and for 100
days after final infusion. Potentially immunologic AEs
were classified as select AEs [43]. A reduced rate of
TRAEs (59% vs 78%, respectively) and grade 3/4 AEs
(13% vs. 35%, respectively) were observed in patients
who received nivolumab compared to patients who were
treated with chemotherapy. Endocrine disorders, primar-
ily hypothyroidism, occurred in 8% of patients. Among
irAEs, gastrointestinal events were less common during
nivolumab compared to SOC (6.8% vs. 14.4%). Other
irAEs such as rash, pruritus and hypothyroidism, how-
ever, were higher in the nivolumab-treated group com-
pared to SOC [43].
In KEYNOTE-012, laboratory safety tests were con-
ducted within ten days of treatment initiation and within
72 h of each subsequent dose [14, 42]. Serious AEs were
monitored for 90 days after the last dose of study treat-
ment up to 34 months and non-serious AEs were moni-
tored for 30 days post-last dose of study treatment up to
32months [14, 42, 47]. Treatment was halted in the
event of a grade 4 toxicity, or a grade 3 toxicity that did
not resolve within 12 weeks of the last treatment dose.
Overall, treatment with pembrolizumab was well-
tolerated. In the expansion cohort of KEYNOTE-012,
only 17% of patients receiving pembrolizumab experi-
enced grade 3/4 adverse events, most commonly alanine
aminotransferase and aspartate aminotransferase eleva-
tions, as well as hyponatremia. Twenty percent of these
patients experienced an irAE, most of which were con-
sidered grade 1/2. Grade 3 irAEs included pneumonitis,
diabetes mellitus, decubitus ulcer, colitis, and liver in-
jury. Three patients (one each: G3 pneumonitis, G3 col-
itis, and G2 interstitial lung disease) discontinued
treatment [42].
In KEYNOTE-040, AEs and laboratory irregularities
were collected throughout treatment and for 30 days
following treatment for low grade toxicities and 90 days
following treatment for serious AEs. Toxicities were
graded using the NCI CTCAE version 4.0. In this study,
fewer patients treated with pembrolizumab experienced
grade ≥ 3 TRAEs compared with SOC (13% vs 36%). The
most common pembrolizumab-associated TRAE was
hypothyroidism (13%) and fatigue with SOC (18%).
Treatment-related deaths occurred in four patients who
received pembrolizumab (unspecified cause, large intes-
tine perforation, malignant neoplasm progression, and
Stevens-Johnson syndrome) and two patients who re-
ceived SOC (malignant neoplasm progression and pneu-
monia) [44].
Some investigators have raised concerns in clinical
trial design that include the quality and completeness of
irAE reporting, noting time to occurrence, and
constraints due to limited follow up periods [101]. For
instance, some studies have only required safety assess-
ment up to 30 days after the last dose, whereas other
studies explicitly exclude reporting of adverse events
that occur more than 30 days after the last dose, or after
starting another cancer treatment [101].
Of note, while most irAEs appear to occur during im-
munotherapy [1, 3–13, 15, 16, 19], there is growing evi-
dence to suggest the existence of post-immunotherapy
irAEs, which occur months or years after treatment dis-
continuation [16–18, 30, 102]. With an increasing num-
ber of neoadjuvant/adjuvant IO trials currently being
conducted in the definitive/curative setting, it will be ne-
cessary to recognize this emerging clinical entity and
perhaps adjust follow-up and reporting times.
Consensus recommendations
The subcommittee discussed when to change clinical man-
agement of patients treated with IO therapies based on
irAEs. The subcommittee felt that general management of
head and neck cancer toxicity is aligned with the practical
management of irAEs in other solid tumor types and pro-
vided recommendations concerning immune-related toxic-
ities specific to head and neck cancer. For further detail
into toxicity management strategies please refer to the
NCCN Clinical Practice Guidelines in Oncology: Manage-
ment of Immunotherapy-Related Toxicities (2019) [103].
The majority of the subcommittee (76%) recommends
evaluating patients with HNSCC treated with checkpoint
blockade for signs of adverse events at least once monthly
during the course of treatment. For those patients who de-
velop an irAE < grade 3, the majority of the subcommittee
recommends continuing ICIs for grade 1 events with the
exception of some neurologic, hematologic or cardiac tox-
icities. For grade 2 events, the subcommittee recommends
stopping IO therapy and providing closely monitored out-
patient treatment, including consideration of oral steroids.
For irAE development ≥ grade 3, the majority of the
subcommittee recommends admitting the patient to the
hospital (79%), administering steroids (77%), and halting
treatment (67%).
The majority of the subcommittee recommended rou-
tine monitoring of thyroid function (94%), neck and
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airway through imaging (62.5%), and AST/ALT levels
(75%). Lipase evaluation was recommended by 44% of
the subcommittee, while brain imaging was only recom-
mended by 6% of members. The subcommittee was split
on whether whole-body imaging is necessary during
treatment.
Concerning thyroid function, the subcommittee rec-
ommends routine patient evaluation during treatment
with anti-PD-1 agents. In patients that develop
hypothyroidism, the majority of the subcommittee (75%)
recommended continuing immunotherapy, providing
levothyroxine for management, and evaluating thyroid
function in two-month intervals.
Moreover, 67% of the subcommittee agreed that pneu-
monitis is not a greater concern in immunotherapy pa-
tients with HNSCC compared to other cancers. However,
the subcommittee did suggest that some patients with
HNSCC may be at a higher risk of developing pulmonary
problems such as those already aspirating, or patients with
previous radiation to the thorax.
In the event of bulky, progressing disease leading to
organ dysfunction or compromise, 53% of the subcom-
mittee recommended halting immunotherapy. Subcom-
mittee members noted that evaluation of the underlying
condition is necessary to determine whether compromis-
ing bulky disease is due to tumor progression versus in-
flammation from immunotherapy, or other cause.
Medical oncologists should obtain surgical consultation
early in their treatment course for patients with a tenu-
ous airway or vascular encasement, even in the setting
of clinical response to immunotherapy. Clinicians should
be aware that delayed irAEs may occur months after dis-
continuation of immunotherapy and patients should be
observed for such toxicities indefinitely [104–107].
Finally, there are occasional unique clinical scenarios.
For instance, patients with some HNSCC- or immune-
related comorbidities were not included in the clinical
trials and the effect of steroid treatment on immune re-
sponse and clinical activity of immunotherapy is not well
understood. Thus, safety considerations for treating a
patient with bulky disease, which may compromise the
airway and/or potentiate vascular blowout, are not well
characterized. Furthermore, complete response of large
tumors after immunotherapy that result in exposure of
major vessels is not well described and may necessitate
reconstructive interventions not previously considered
in the setting of metastatic or locoregionally advanced
disease.
6. Are there categories of patients with HNSCC who
should not receive immunotherapy?
Current FDA approvals for nivolumab and pembrolizu-
mab for the treatment of patients with R/M HNSCC
have no eligibility restrictions [108, 109]. For instance,
these approvals suggest that patients with Epstein-Barr
virus (EBV)-associated nasopharyngeal carcinoma (NPC)
also qualify for immune checkpoint therapies [110].
Additionally, patients reliant on steroids or with under-
lying immune dysfunction are also technically eligible to
receive immunotherapy even though they were not usu-
ally included in pivotal clinical trials. The subcommittee
discussed whether specific groups of HNSCC patients
would not be good candidates for treatment with ICIs.
Literature review and analysis
Patient inclusion criteria were similar in nivolumab and
pembrolizumab clinical trials. All trials required an
ECOG performance status of 0 or 1. Patient exclusion
criteria for Checkmate 141 enrollment included brain
metastases, active immunosuppression, or histologically
confirmed R/M carcinoma of the nasopharynx, squa-
mous cell carcinoma of unknown primary, and salivary
gland or non-squamous histology [43].
Exclusion criteria for pembrolizumab trials KEYNOTE-
012, KEYNOTE-040, KEYNOTE-028 and KEYNOTE-048
all included active autoimmune disease, receipt of
systemic steroid therapy above a physiologic dose, CNS
metastases, active infection requiring treatment (including
HIV, hepatitis B and C), and known history of HIV [14].
Particular to KEYNOTE-048, participant ineligibility
included a primary tumor site of nasopharynx (any
histology).
A systematic review of 13 articles plus 4 meeting pre-
sentations was conducted to determine if ICI therapy
was safe and efficacious in patients with HIV infection
and advanced stage cancer, including NSCLC, melanoma
and Kaposi sarcoma. This analysis was comprised of 73
patients from 13 articles (11 case reports and 2 case
series) and 4 meeting abstracts. Sixty-two patients were
treated with anti–PD-1 therapy, 6 with anti–CTLA-4
therapy, 4 with anti–PD-1/CTLA-4 therapy, and 1 with
sequential ipilimumab and nivolumab therapy. Among
34 patients with known pre-treatment and post-
treatment HIV loads, HIV remained suppressed in 26 of
the 28 (93%) with undetectable HIV load. ORR was 30%
for NSCLC, 27% for melanoma, and 63% for Kaposi
sarcoma. Results demonstrated that ICI therapy was
generally well tolerated, inducing grade 3 or higher
immune-related adverse events identified in 6 of 70
patients. Further, this study found no association with
adverse changes in HIV load or CD4 cell count [111].
Case reports have been presented demonstrating re-
sponse to ipilimumab and/or nivolumab in HIV+ pa-
tients with advanced melanoma without any detriment
[112]. Interim results from the CITN-12 clinical trial
suggested that pembrolizumab was safe for HIV+ pa-
tients with cancer on anti-retroviral therapy [113].
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Moreover, PD-1 has been shown to be upregulated in
hepatitis C virus (HCV)-specific CD8+ cells, suggesting
that although patients with chronic hepatitis have trad-
itionally been excluded from clinical trials, anti–PD-1
therapy may have beneficial effects in patients with HCV
infection. A case report details the use of anti-PD-1 to
treat metastatic Merkel cell carcinoma (MCC) in a pa-
tient with untreated chronic HCV infection. Treatment
resulted in a rapid antitumor response as well as a rapid
decline in HCV RNA without apparent hepatocellular
injury. Such results suggested that anti–PD-1 therapy
may induce antitumor immune responses while also
working to restore antiviral T-cell function and over-
come viral immune escape. As such, there are several
ongoing clinical trials of anti–PD-1 checkpoint blockade
in patients with hepatocellular carcinomas which do
allow the enrollment of patients with untreated HCV
(NCT02658019, NCT02940496, and NCT02702414)
[114].
Consensus recommendations
The majority of subcommittee members agreed that the
presence of recurrent and/or metastatic disease (89%),
previous platinum therapy (78%) and patient performance
status (56%), influence whether they would recommend
immunotherapy for a specific patient. Additionally, 83% of
the subcommittee noted that clinical trial eligibility and
availability would also play a role in determining whether
to administer FDA-approved immunotherapies. It should
be noted that this vote was taken prior to approval of
pembrolizumab in 1st line R/M disease (on June 10,
2019).
Overall, the subcommittee recognized that while the
data regarding patients with autoimmune disease are
sparse, the pool of patients considered eligible is increas-
ing. For instance, the subcommittee agrees that age
(89%), lung metastases (89%) or co-morbidities (75%)
are not reasons to disqualify a patient from receiving
anti-PD-1 immunotherapy, and that elderly patients ac-
tually tolerate immunotherapies better than cytotoxic
therapies. Additionally, the subcommittee agrees (81%)
that patients with autoimmune disease should not auto-
matically be excluded but rather, the decision should be
tailored to the specific disease. The subcommittee
recommends that patients with controlled diseases such
as Hepatitis C (75%) are generally suitable for ICI treat-
ment, as are HIV+ patients (75%) with normal CD4+ T
cell counts and who are on antiretroviral therapy. More-
over, a substantial minority of the subcommittee also
agreed that significant burden and pace of disease re-
quiring rapid tumor burden reduction (44%) and steroid
dosing for any reason over 10 mg/day of prednisone or
equivalent (38%) would be reasons not to give anti-PD-1
monotherapy to a platinum chemotherapy-refractory
HNSCC patient.
7. What is the role of immunotherapy in rare head and
neck cancer subtypes?
As very few studies have sought to investigate whether
immunotherapy is safe and effective in treating rare sub-
classes of HNC, questions remain as to whether patients
with these rare subclasses should also qualify for im-
munotherapy. Therefore, the subcommittee discussed
whether patients with cutaneous squamous cell carcin-
oma (cSCC), NPC, salivary gland, ACC, and thyroid can-
cer should be under consideration for checkpoint
blockade.
Literature review and analysis
cSCC is a relatively rare cancer of the head and neck but
represents 20% of all non-melanoma skin cancers [115].
Advanced cSCC carries a poor prognosis and until this
year there were no FDA-approved systemic therapies
[116–118]. However, given a high TMB and disease-risk
associated with immunosuppression [118], a phase I
dose-escalation study (NCT02383212) and subsequent,
phase 2 pivotal study (NCT02760498), examined the
PD-1 inhibitor cemiplimab in patients with advanced
cSCC. These studies resulted in a FDA approval for
cemiplimab on September 28, 2018 for the treatment of
patients with metastatic or locally-advanced cSCC who
are not candidates for curative surgery or radiation. Ap-
proval was based on a clinically meaningful and durable
ORR (47.2% [95% CI: 38–47]) of 108 total patients (75
with metastatic cSCC and 33 with LA cSCC) in these
two open-label clinical trials at the median follow-up
time of 8.9 months (4% CR and 44% PR) with 61% of re-
sponses reaching ≥ six months in the metastatic disease
cohort of the phase 2 study [119].
Examining another rare cancer of the head and neck,
KEYNOTE-028 included a cohort for patients with re-
current or metastatic PD-L1 positive NPC who had
failed on prior standard therapy. ORR was 25.9% (95%
CI: 11.1–46.3), with 26% of patients experiencing PR
and 52% of patients with SD. Drug-related AEs occurred
in 74% of patients (30% grade 3/4), most commonly
pruritus (26%), fatigue (19%), and hypothyroidism (19%)
[119]. Additionally, the phase 2 study, NCI-9742
(NCT02339558), evaluated nivolumab antitumor efficacy
in heavily pretreated patients with R/M-NPC [120]. Of
44 patients, ORR was 20.5% (CR = 1; PR = 8), 1-year OS
rate was 59% (95% CI, 44.3 to 78.5%), and 1-year PFS
rate was 19.3% (95% CI, 10.1 to 37.2%) [120].
Atezolizumab (anti-PD-L1) has also shown promising
efficacy for patients with NPC as demonstrated in the
HNC cohort of the phase 1 PCD4989g clinical trial
(NCT01375842) [121]. Of the 32 patients enrolled,
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objective responses by RECIST v1.1 occurred in 22% of
patients, with median of PFS 2.6 months (range 0.5–
48.4), and median OS 6.0 months (0.5–51.6+) [121].
Additionally, results from two single-arm, phase 1 tri-
als examined camrelizumab, a PD-1 inhibitor, in the
treatment of R/M-NPC. Safety and preliminary antitu-
mor efficacy were reported for camrelizumab monother-
apy in the second-line (NCT02721589) and in
combination with gemcitabine and cisplatin in the first-
line (NCT03121716) compared to SOC [122]. In the
camrelizumab monotherapy cohort 34% (95% CI: 24–44)
of evaluable patients experienced an ORR with a median
follow-up of 9.9 months (IQR 8.1–11.7). Sixteen percent
of patients experienced TRAEs of grade 3 or 4. For the
combination study, 91% (95% CI: 72–97) of evaluable
patients experienced an ORR with a median follow-up
time of 10.2 months (IQR 9.7–10.8), and 87% of patients
developed grade 3 or 4 TRAEs [122].
Additional rare cancers of the head and neck include
salivary gland carcinoma (SGC) and thyroid cancer.
KEYNOTE-028 reported that in patients with PD-L1-
positive (≥1% of tumor or stroma cells) unresectable or
metastatic salivary gland carcinoma, pembrolizumab
demonstrated a RR of 12% and a manageable safety pro-
file [123]. A phase I/II study (NCT02404441) character-
ized the safety and efficacy of spartalizumab, a
monoclonal antibody (mAb) which binds PD-1, in pa-
tients with anaplastic thyroid cancer (ATC), an aggres-
sive cancer with limited treatment options [124]. At the
data cut-off date of Jan 23, 2018, the ORR by RECIST
1.1 (confirmed + unconfirmed PRs) was 5/30 (17%), with
four CRs [124]. Furthermore, new data have prompted
the phase 2 clinical trial (NCT03072160) which is inves-
tigating the use of pembrolizumab for treatment of TKI-
naïve patients with recurrent or metastatic medullary
thyroid carcinoma (MTC), for whom surgery is not a
curative option.
Consensus recommendations
Category 1 evidence led to the FDA approval of the
checkpoint inhibitor cemiplimab for treatment of
patients with advanced cSCC. Prescribing dose informa-
tion is listed as 350 mg administered as an intravenous
infusion over 30 min every three weeks, until disease
progression or unacceptable toxicity.
The majority of the subcommittee agreed with the rec-
ommendation of providing immune checkpoint inhib-
ition to patients with cutaneous tumors in the head and
neck area. The subcommittee recognizes the need for
more clinical data concerning immunotherapy efficacy
in the treatment of rare HNC. Many subcommittee
members noted that existing clinical trial data for these
rare cases have been generally positive, and support clin-
ical trial enrollment for these patients. However, in lieu
of an available clinical trial, 43% of the subcommittee
recommends treating with SOC or targeted therapy
based on gene expression analyses.
The subcommittee agreed (76.5%) that patients with
NPC are distinct from other HNSCC patients. Reasoning
for separation is primarily due to etiological differences
in disease, which results in differential SOC. Of the
members that recommended separate consideration of
NPC patients, 57% recommended clinical trial enroll-
ment as the primary treatment option for recurrent and
metastatic disease. Multiple clinical trials in patients
with platinum refractory NPC have demonstrated single-
agent activity of PD-1/PD-L1 inhibitors with response
rates of ~ 20–25%. Therefore, where clinical trial enroll-
ment is not feasible, patients with platinum-refractory
NPC may derive clinical benefit from single-agent PD-1/
PD-L1 checkpoint blockade.
8. How should immunotherapy be incorporated within a
novel combination systemic therapy strategy for HNSCC?
New immunotherapy combination strategies are critical
for increasing patient response and combating immune
resistance that may arise during treatment. Novel immu-
notherapeutic strategies are currently being evaluated for
the treatment of patients with HNSCC with the goal of
improving response rates, OS, and PFS. Ongoing clinical
trials are investigating efficacy of immunotherapies that
have approvals in other disease settings, such as melan-
oma, as well as potential multi-modality combination
strategies. The subcommittee outlined the potential of
various immunotherapies currently in clinical trials for the
treatment of patients with HNSCC, organized according
to the following treatment settings: (A) Recurrent/Meta-
static; (B) Adjuvant; (C) Definitive; (D) Neoadjuvant
(Table 2) and detailed several phase 2 and 3 trials of sig-
nificance that have reported out.
Literature review and analysis
IO-chemotherapy The KEYNOTE-048 phase III clinical
trial examined pembrolizumab + chemotherapy (plat-
inum + 5-fluorouracil) vs. cetuximab + chemotherapy in
patients with previously untreated R/M HNSCC [50].
Pembrolizumab in combination with platinum and fluo-
rouracil (FU) was recently approved for use in all pa-
tients with R/M HNSCC irrespective of CPS.
IO-EGFR inhibitors Monalizumab is a monoclonal
antibody that blocks the NKG2A receptor on NK and
T cells. A phase 2 clinical study of Monalizumab and
cetuximab in patients with R/M HNSCC who pro-
gressed after platinum based chemotherapy showed a
promising ORR of 27.5%. Responses were observed in
patients naïve to immunotherapy (35%) and patients
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Table 2 Incorporation of immunotherapy within novel combination therapy strategies for HNSCC
Treatment Setting
Trial Description Objective Results
A. Recurrent/Metastatic
IO-Chemotherapy Active8
(NCT01836029)
Phase 2. EXTREME + motolimod vs.
EXTREME + placebo.
Combination of CT/cetuximab
with an innate immune stimulator
via toll-like receptor antagonism.
Adding motolimod to the
EXTREME regimen did not improve
PFS or OS in the intent-to-treat
population [125].
KEYNOTE-048
(NCT02358031)
Phase 3. Pembrolizumab
monotherapy vs. pembrolizumab
+ platinum-based CT (cisplatin or
carboplatin) + 5-Fluorouracil (5-FU)
vs. cetuximab + platinum-based
CT (cisplatin or carboplatin) + 5-FU.
Pembrolizumab as first-line treat-
ment of R/M HNSCC.
Pembrolizumab alone improved
OS over SOC in the PD-L1 CPS
≥20 (p = 0.0007) and≥ 1 (p =
0.0086) populations. Pembrolizu-
mab + CT significantly improved
OS in the total population (p =
0.0034) [126].
IO-EGFR inhibitors IPH2201–203
NCT02643550
Phase 2. Monalizumab +
cetuximab in patients with R/M
HNSCC who progressed after
platinum-based chemotherapy.
Dual targeting by reducing
inhibitory signaling and unleashing
NK and T Cell responses with
monalizumab and enhancing
cetuximab mediated ADCC.
Median PFS and OS: 5.0 and 10.3
months, respectively. ORR: 27.5%.
Responses were observed in IO
naïve (35%) and IO pretreated
patients (18%). Median DOR: 5.6
months [127].
Dual Checkpoint
Blockade
CheckMate-
651
(NCT02741570)
Phase 3. Nivolumab + ipilimumab
vs. SOC (Extreme Study Regimen)
as first-line treatment in patients
With R/M HNSCC.
Combination nivolumab +
ipilimumab has shown significant
promise in patients with NSCLC,
advanced melanoma and
advanced RCC [128].
Results ongoing. Primary outcome
measures include OS and PFS in
patients with PD-L1 expressing
tumors.
CONDOR
(NCT02207530)
Phase 2. Durvalumab +
tremelimumab vs. durvalumab
monotherapy vs. tremelimumab
monotherapy in pts. with R/M
HNSCC refractory to platinum-
based therapy.
The PD-L1 and CTLA-4 pathways
are non-redundant and preclinical
data indicate targeting both may
induce synergistic antitumor
effects.
In combination, durvalumab
monotherapy and tremelimumab
monotherapy cohorts, median OS:
7.6, 6.0 and 5.5 months; median
PFS: 2.0, 1.9, 1.9; and ORR*IRC: 7.8,
9.2 and 1.6% [129].
KESTREL
(NCT02551159)
Phase 3. Durvalumab +
tremelimumab vs durvalumab
monotherapy vs. SOC CT in
treatment naïve R/M HNSCC
patients.
First-line treatment for R/M HNSCC
targeting both PD-L1 and CTLA-4
pathways has potential for syner-
gistic antitumor effects.
Results ongoing [130].
EAGLE
(NCT02369874)
Phase 3. Durvalumab monotherapy
vs. durvalumab + tremelimumab
vs. SOC in R/M. Eligible patients
are immunotherapy naïve but
have progressed on a platinum-
containing regimen or within 6
months of multimodality platinum
therapy.
Second-line treatment for R/M
HNSCC targeting both PD-1 and
CTLA-4 pathways may induce syn-
ergistic antitumor effects.
Failed to meet primary endpoint
of improved overall survival [131].
IO-IO: Checkpoint +
innate immune
activation
MASTERKEY-
232
(NCT02626000)
Phase 1b/3. Combination
pembrolizumab + talimogene
laherparepvec (T-VEC) as second-
line therapy in R/M HNSCC
patients.
T-VEC is the first FDA-approved
oncolytic immunotherapy which
works to systemically enhance the
antitumor immune response [132]
[133].
Twenty-four (66.7%) patients
experienced a grade 3 or higher
TRAE, with 5 related to T-VEC and
3 related to Pembrolizumab.
ORR*IR in 6 patients: 16.7%; 5 PD-
L1-positive. Objective response/SD
in 14 patients: 38.9%; 11 PD-L1-
positive. 24/36 (66.7%) pts. had
grade 3 or higher treatment-
emergent adverse events [133].
KEYNOTE-184
(NCT02521870)
Phase 1b/2. Intratumoral Injections
of SD-101 in Combination With
Pembrolizumab in treatment-naïve
R/M HNSCC patients.
SD-101 is a synthetic CpG-ODN
agonist of TLR 9 that stimulates
dendritic cells to release IFN-alpha
and mature into antigen present-
ing cells to activate T cell anti-
tumor responses.
Of the 10 evaluable patients,
ORR*IR by radiographic images
was 33%, compared to 15% by
pembrolizumab therapy alone
[134].
(NCT01714739) Phase 1/2. Lirilumab + Nivolumab
in HNSCC.
Utilization of Lirilumab, a mAb that
blocks inhibitory killer Ig-like recep-
tors (KIRs) on NK cells, in patients
ORR of 24% in combination
compared to 13% by nivolumab
alone, with 17% reductions in
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Table 2 Incorporation of immunotherapy within novel combination therapy strategies for HNSCC (Continued)
Treatment Setting
Trial Description Objective Results
with relapsed, advanced HNSCC. tumor burden ≥80%. However,
Innate closed the trial due to a
lack of efficacy on November 22,
2017 (press release).
STING
(NCT02675439)
Phase 1. STING agonist MIW815
(ADU-S100) + ipilimumab vs.
pembrolizumab in advanced solid
tumors
The STING (stimulator of interferon
genes) pathway is a critical
component of the antitumor
response. ADU-S100 is a cyclic di-
nucleotide that activates all known
human STING alleles.
Despite data demonstrating
stimulation of the immune system
by STING, the role of the STING
pathway in anti-tumor immunity is
still unclear [135, 136].
IO-IO: checkpoint +
vaccine
(NCT02426892) Phase 2. Nivolumab + ISA101 in
patients with incurable
oropharyngeal cancer.
To determine if nivolumab efficacy
is amplified through treatment
with ISA 101, a synthetic long-
peptide HPV-16 vaccine inducing
HPV-specific T cells, in patients
with incurable HPV-16-positive
cancer.
Median PFS: 2.7 months (95% CI,
2.5–9.4 months) and median OS:
17.5 months (95% CI, 17.5 months
to inestimable). Response was
positively correlated with tumor
cell PD-L1 positivity (≥1%) [137].
36% ORR in patients with oropha-
ryngeal cancer compared to 16%
by nivolumab alone [43].
(NCT03162224) Phase 1b/2a. Safety and efficacy of
MEDI0457 + durvalumab in
patients with HPV+ R/M HNSCC.
Eligible patients include those with
confirmed HPV+ HNSCC refractory
to platinum-based CT.
Currently recruiting. [138].
Adoptive T cell
therapies
C-145-03
(NCT03083873)
Phase 2. Adoptive cell therapy
with autologous TIL infusion (LN-
145) followed by IL-2 after a non-
myeloablative lymphodepletion R/
M HNSCC patients.
Despite HNSCC tumor
heterogeneity, many tumors are
either virally-associated or carry
high mutation loads that increase
the potential antigens targeted by
TIL ACT [139].
Results ongoing. Preliminary safety
and efficacy were reported. 3/8
patients treated with LN-145
achieved a PR as per RECIST 1.1
(press release).
(NCT01818323) Phase 1. Dose-escalation trial of
T4-immunotherapy in patients
with HNSCC without lymphodeple-
tion [140].
T4 immunotherapy includes
patient T cells engineered to
express a panErbB-targeted CAR,
co-expressed with a chimeric cyto-
kine receptor that allows
interleukin-4-mediated CAR T cell
proliferation [141].
SD was observed in patients with
≥10 × 107 T4+ T-cells at 6-weeks
post-intra-tumoral injection. An
overall disease control rate of 69%
was reported (RECIST 1.1) [140].
(NCT02379520) Treatment of metastatic HPV16+
epithelial cancers by a single
intravenous infusion of engineered
E6-targeting T cells [142].
HPV-specific T-cells (HPVST) are de-
rived from patients with HPV-
related cancers to evaluate if these
cells can survive in the blood and
subsequently eliminate the HPV-
associated tumor [143].
2/9 patients receiving the highest
dose experienced tumor
responses; one patient with a 6-
month PR experienced complete
regression of one lesion and par-
tial regression of two lesions and
no evidence of disease three years
later [142].
(NCT02858310) Phase 1/2.
Trial of T Cell Receptor gene
therapy targeting HPV-16 E7 with
or without PD-1 blockade for
HPV+ cancers [144].
To determine a safe dose and
efficacy of E7 TCR cells and
whether these cells will have
efficacy in treating HPV+ patients.
Currently recruiting. T cells were
successfully engineered to target
HPV-16 E7 and were able to medi-
ate regression of HPV-16+ human
cancers in an animal model [145].
IO-targeted therapy (NCT02501096) Phase 1b/2. Lenvatinib +
pembrolizumab combination
therapy.
First systemic combination of a TKI
and immunotherapy for patients
with HNSCC.
ORR*IR at 24 weeks: 36.4% (95% CI:
17.2–59.3). Grade 3/4 AEs occurred
in 91% of patients, with 4 patients
(18%) having to discontinue study
treatment due to AEs [146].
Bispecific antibodies,
fusion proteins
(NCT02517398) Phase 1. M7824 given once every
2 weeks at different dose levels in
metastatic or locally advanced
solid tumors.
Genome wide association studies
point to transforming growth
factor-β (TGF-β) which is overex-
pressed in HPV+ cancers [147].
ORR*IRC of 45.5% in patients with
known HPV+ disease and an
overall disease reduction in 56%
(9/16) of patients [147].
IO-IO: checkpoint +
microenvironment/
immunometabolism
(NCT02499328) Phase 1b/2. Durvalumab +
AZD9150 (STATi) or AZD5069
(CX2i) in HNSCC patients.
Metabolic competition exists
between tumor and immune cells
and there is evolving evidence
that combining therapies that
A 25% ORR (5PR) was observed in
patients with anti-PD-L1 treatment
naïve R/M HNSCC patients, with
responses observed in PD-L1+/−
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Table 2 Incorporation of immunotherapy within novel combination therapy strategies for HNSCC (Continued)
Treatment Setting
Trial Description Objective Results
directly dampen tumor
metabolism with immunotherapy
could be a promising therapeutic
strategy.
patients as well as HPV- patients
[148].
Photoimmunotherapy (NCT02422979) Phase 2a. Non-thermal red light
was applied to tumors 24 h after
intravenous infusion of RM1929.
Light was applied by surface illu-
mination for superficial disease or
interstitial illumination via intratu-
moral placement of fiber optic dif-
fusers for deep tumors.
Photoimmunotherapy is an
emerging therapeutic strategy that
combines photodynamic therapy
with immunotherapy, i.e. RM-1929,
a novel light-activated drug [149].
Median PFS for 28 evaluable
patients was 173 days (5.7 months).
Median OS for entire 30 patient
cohort was 278 days (9.1 months).
ORR*IRC of 28% (8/28), CR of 14%
(4/28) [149]. Therapeutic response
was calculated using CT RECIST
1.1.
IO-radiotherapy
(SBRT)
(NCT02684253) Phase 2. Nivolumab + SBRT vs.
nivolumab monotherapy in
metastatic HNSCC patients,
including nasopharynx [150].
Radiation may act as an in situ
vaccine, which propagates via
epitope spreading to enhance
anti-tumor immunity beyond the
radiated lesion and enhance im-
mune control of distant disease
(abscopal effect) [150].
OS at 1 year for Nivolumab
monotherapy versus nivolumab +
SBRT: 64% (95% CI: 47, 88%)
compared to 53% (95% CI: 36,
79%) (p = 0.79), respectively. ORR*IR
for nivolumab monotherapy:
26.9% (95% CI: 13.7, 46.1%), while
nivolumab plus SBRT: 22.2% (95%
CI: 10.6, 40.8%) [150].
B. Adjuvant
PATHWay
Study
(NCT02841748)
Phase 2. Pembrolizumab vs.
placebo in advanced HNSCC.
To test pembrolizumab in pts. with
head and neck cancers at high risk
for recurrence or low-volume re-
sidual disease [151].
Currently recruiting. Eligible
patients must have HNSCC,
completed therapy with definitive
intent, and have an estimated risk
of recurrence ≥40–50% [151].
NRG HN-003
(NCT02775812)
Phase 1. Adjuvant pembrolizumab
+ cisplatin and IMRT in patients
with high-risk, HPV-, stage III-IV
HNSCC.
Giving pembrolizumab with
cisplatin and IMRT to boost
immune response.
Active. Primary outcome is to
determine the recommended
phase II dose for the combination
of pembrolizumab and cisplatin-
radiotherapy in patients with high-
risk, HPV- HNSCC, based upon
dose-limiting toxicity.
ECOG ACRIN
EA3161
Phase 2/3. Definitive
chemoradiation followed by
nivolumab or observation for
intermediate risk patients with
locally advanced, HPV+ SCC of the
oropharynx.
Importance of focusing specifically
on HPV-related locally advanced
OPSCC as a unique disease entity.
Will determine whether a
maintenance approach with a
single agent ICI following
definitive therapy would alter PF
or OS for high-risk HPV+ disease.
WO40242
(NCT03452137)
Phase 3. Atezolizumab vs. placebo
for high risk stage IV HPV- or stage
III HPV+ HNSCC after definitive
local therapy.
To evaluate efficacy and safety of
atezolizumab as adjuvant therapy.
Currently recruiting. Primary
outcomes will include
Independent Review Facility
assessed Event Free Survival (IRF
assessed EFS) and OS.
C. Definitive
RTOG-3504
(NCT02764593)
Phase 2. Adding nivolumab to
standard cetuximab-RT for patients
with newly diagnosed intermedi-
ate/high-risk loco-regionally ad-
vanced HNSCC [152].
Immunotherapy is added to
enhance other conventional
therapies such as surgery, CT and
RT.
Nivo is safe and reasonable to
administer in combination with a
cetuximab-RT regimen for patients
with newly diagnosed IR/HR
HNSCC [152].
GORTEC 2015–
01
(NCT02707588)
Phase 2. Pembrolizumab or
cetuximab + RT in LA HNSCC
patients.
To determine synergistic effects
when combining ICI with RT
compared to SOC cetuximab plus
RT.
Decrease in serious AEs in
pembrolizumab arm (78% pts) vs.
cetuximab arm (94% pts) [153].
GORTEC 2017–
01 (REACH)
(NCT02999087)
Phase 3. Avelumab + cetuximab
and RT vs. SOC in LA HNSCC.
Expansion of GORTEC 2015–01.
Based on the hypothesis of a
synergistic effect upon
combination of avelumab with
cetuximab + RT.
This trial achieved an acceptable
safety profile and was granted
approval to continue by the Data
and Safety Monitoring Committee
[154].
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Table 2 Incorporation of immunotherapy within novel combination therapy strategies for HNSCC (Continued)
Treatment Setting
Trial Description Objective Results
(NCT02609503) Phase 2. Pembrolizumab with
concurrent RT in cisplatin-ineligible
LA HNSCC patients.
Immunotherapy is added to
intensity-modulated RT (IMRT) for
synergistic effects.
All patients completed 70Gy
radiation and demonstrated low
levels of toxicity [155].
NRG HN-004
(NCT03258554)
Phase 2/3. Standard IMRT +
durvalumab vs. cetuximab in
cisplatin-ineligible patients with
stage III-IV HNSCC.
Immunotherapy compared to
targeted therapy in addition to RT
to compare synergistic effects.
Recruitment currently suspended.
(NCT02586207) Phase 1. Pembrolizumab plus
weekly cisplatin-based chemoradi-
ation (CRT).
Immunotherapy is added to CRT
for synergistic effects.
78% of enrolled pts. completed all
planned pembrolizumab doses. All
pts. completed the full 70 Gy
radiation dose and 85% received
the target dose of cisplatin (≥200
mg/m2) [156].
(NCT02777385) Phase 2. Pembrolizumab +
cisplatin and IMRT was compared
by sequencing of PD-1 blockade
during and after CRT.
Immunotherapy is added to CT
and RT at different sequences to
determine synergistic effects.
Currently recruiting.
JAVELIN
(NCT02952586)
Phase 3. Avelumab + SOC CRT vs.
SOC CRT in LA HNSCC patients.
Combining avelumab + CRT may
synergistically activate multiple
immune-mediated mechanisms
and improve long-term disease
control [157].
Currently recruiting.
KEYNOTE-412
(NCT03040999)
Phase 3. Pembrolizumab or
placebo + CRT in LA HNSCC
patients.
CRT has immunomodulatory
effects; preclinical data suggest
efficacy can be improved by
adding pembrolizumab [158].
Currently recruiting. Adult pts. with
newly diagnosed, pathologically
proven, treatment-naive LA-HNSCC
will be enrolled [158].
(NCT03349710) Phase 3. Nivolumab monotherapy
vs. nivolumab + cisplatin, in
combination with RT in cisplatin-
ineligible or eligible will be
assessed in LA HNSCC patients.
To determine whether nivolumab
in combination with RT is more
effective than cetuximab in
combination with RT.
Active, not recruiting. Largest trial
of its kind with a planned
participant count of 1046.
KEYCHAIN
(NCT03383094)
Phase 2. Pembrolizumab + RT vs.
Bolus cisplatin + RT for
intermediate risk P16-positive
HNSCC.
To compare PFS for head-to-head
comparison of immunotherapy vs.
chemotherapy for intermediate risk
previously untreated HNSCC.
Currently recruiting.
D. Neoadjuvant
Checkmate-
358
(NCT02488759)
Phase 1/2. Neoadjuvant nivolumab
in patients with resectable HPV+
or HPV− HNSCC and EBV-
associated NPC.
Treatment options for patients
with R/M NPC are limited to
palliative chemotherapy.
As of database lock, pre-surgery
tumor reduction per CT scan was
observed in 11 of 23 (48%) evalu-
able pts. (5/10 HPV+ and 6/13 HPV
−); 3 pts. had tumor reduction
≥40% (largest reduction, 75%)
[159].
(NCT02296684) Phase 2. Neoadjuvant
pembrolizumab prior to surgical
resection in HPV- LA HNSCC.
A “preoperative window,” study
underway in HNSCC.
Preliminary analyses revealed no
serious TRAEs resulting in surgical
delays or complications. Data
supported an anti-tumor effect fol-
lowing a single dose of pembroli-
zumab [160].
(NCT02641093) Phase 2. Pembrolizumab in
combination with SOC surgery
followed by RT +/− cisplatin.
To test the ability of
pembrolizumab to improve
locoregional recurrence and
distant metastatic rates in high-risk
patients with LA HNSCC treated
with current SOC surgical
approaches.
47% of patients demonstrated a
pathological response – high
immune cell infiltration and
amplified PD-L1 (> 10% tumor ef-
fect) and 32% achieved a major re-
sponse (> 70% tumor effect). 1
patient had CR [161].
(NCT02274155) Phase 1. Anti-OX40 antibody,
MEDI6469, given prior to surgery
in patients with advanced HNSCC.
Immunotherapy given prior to
surgery to enhance immune
response.
This pre-surgery therapy proved
both safe and effective, inducing
activation and proliferation of T
cells as well as expansion of tumor
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who had received prior immunotherapy with PD-1
antibodies (18%). Median PFS and OS are 5.0 and
10.3 months, respectively. The safety of the combin-
ation was acceptable with no potentiation of cetuxi-
mab adverse events [127, 163].
Dual checkpoint blockade The phase II CONDOR clin-
ical trial is investigating efficacy of combination anti-PD-L1
durvalumab + anti-CTLA-4 tremelimumab vs. durvalumab
monotherapy vs. tremelimumab monotherapy in patients
with R/M HNSCC and low tumor PD-L1 status. ORR of
patients was 7.8% for durvalumab plus tremelimumab
combination therapy, 9.2% for the durvalumab
monotherapy, and 1.6% for the tremelimumab monother-
apy. Median OS was 7.6months in the combination cohort
compared to 6.0months for patients receiving durvalumab
monotherapy and 5.5months for patients in the tremelimu-
mab monotherapy cohort. Overall incidence of TRAEs was
57.9% in the combination cohort, with 15.8% grade 3/4 and
one reported death. TRAEs in the durvalumab monother-
apy occurred in 63.1% of patients with grade 3/4 incidence
at 12.3%. The tremelimumab cohort demonstrated a TRAE
incidence of 55.4% with 16.9% grade 3/4 [129].
IO-IO: checkpoint + vaccine To induce an effective
immune response and avoid targeting of self-antigens
Table 2 Incorporation of immunotherapy within novel combination therapy strategies for HNSCC (Continued)
Treatment Setting
Trial Description Objective Results
reactive T cells within the tumor
after infusion [162].
LCC 1621
(NCT03174275)
Phase 2. Induction CT with
carboplatin, nab-paclitaxel, and
durvalumab prior to surgery in
previously untreated stage III-IV
HNSCC.
To test combination CT +
immunotherapy to increase
response to therapy and decrease
side effects associated with RT.
Recruiting. Primary outcome
measure will determine the
pathologic complete response rate
(pCRR) after induction CT.
OPTIMA-II
(NCT03107182)
Phase 2. Combination carboplatin,
nab-paclitaxel, and nivolumab
followed by TransOral Robotic Sur-
gery or RT/CRT after induction CT
in HPV+ OSCC patients.
To determine radiologic response
to induction CT with nivolumab.
Results ongoing. Primary outcome
measure will evaluate tumor
shrinkage (%) to measure the deep
response rate (DRR). DRR is
defined as ≥50% tumor shrinkage
by RECIST 1.1.
KEO
(NCT03325465)
Phase 2. Neoadjuvant
pembrolizumab + epacadostat
prior to surgery in HNSCC patients.
To define the rate of major
treatment effect to neoadjuvant
pembrolizumab plus epacadostat
immunotherapy in HNSCC
compared to data from
neoadjuvant pembrolizumab
treatment alone.
Not yet recruiting. Primary
outcome will measure the rate of
major treatment effect (50%
resolution of tumor with active
immune response).
NIRT
(NCT03247712)
Phase 1/2. Nivolumab
administration + RT prior to
restaging and surgical resection,
followed by nivolumab.
Integrating nivolumab and
hypofractionated RT to down-
stage prior to definitive surgery in
HNSCC.
Recruiting. Primary outcome
measure is the number of patients
with an unplanned delay to
surgery.
ADXS
(NCT02002182)
Phase 2. Vaccination prior to
robotic surgery in HPV+
oropharyngeal cancer.
A neoadjuvant study to determine
if ADXS11–001 vaccine will
stimulate the body’s defense
system before transoral surgery.
Results ongoing. The primary
outcome is HPV E6/E7-specific
CD8+ cytotoxic lymphocyte
responses at different time points.
Secondary outcomes include
toxicity.
(NCT02827838) Phase 2. Durvalumab treatment
prior to surgery for patients with
oral cavity or oropharynx cancer.
To investigate the effect of
durvalumab on local and systemic
immune activation by HPV status
in patients with oral cavity and
oropharynx HNSCC.
Recruiting. Primary outcome
measures include assessment of
immune effectors, immune-
regulatory miR responses, and sys-
temic responses to HPV and sys-
temic immune response to tumor
associated antigens.
(NCT02812524) Phase 1. Intratumoral injections of
ipilimumab before surgical
resection in HNSCC patients.
To test the feasibility of the
administration of intratumoral
injections of ipilimumab prior to
surgical resection, and immune
system response to treatment.
Recruiting. The primary objective is
to assess safety, as determined by
the number of delayed surgeries.
1. *IRC: Response evaluation by an independent review committee
2. *IR: Response evaluation by investigator review
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and overcome tolerance, vaccination would ideally utilize
antigens that are expressed only on tumor cells and not
on normal cells, i.e. tumor-specific antigens (TSA) in-
cluding viral proteins and tumor-specific mutated anti-
gens or “neoantigens.” Numerous types of cancer
vaccines have been tested in preclinical models and in
clinical trials. These include peptide vaccines, tumor
lysates, DNA or RNA vaccines, and cellular vaccines in-
cluding dendritic cells that have been exposed to activa-
tion signals. Results of one such effort were reported
from a phase 2 trial investigating the combination ther-
apy nivolumab plus ISA101, a synthetic long-peptide
vaccine directed against human papillomavirus 16
(HPV16) for the treatment of patients with incurable
oropharyngeal cancer [137]. The primary endpoint of
ORR was met at 33%. While the trial was open to
all patients with HPV16-related cancers, of the 22
patients with oropharyngeal cancer, 36% achieved an
objective response compared to an ORR of 16% by
treatment with nivolumab alone [43, 137]. Median
PFS was 2.7 months (95% CI: 2.5–9.4 months) and
median OS was 17.5 months (95% CI: 17.5 months to
inestimable) [137]. Response correlated with tumor
cell PD-L1 positivity (≥1%).
Definitive treatment While the value of immunother-
apy is now recognized in metastatic disease, its value in
definitive therapy in HNSCC is an area of active investi-
gation. Here, the addition of immunotherapy is used to
enhance other conventional therapies such as surgery,
chemotherapy and radiotherapy. There are many on-
going clinical trials, which are working to integrate im-
munotherapy into existing treatment sequences of
surgery plus adjuvant radiotherapy or concurrent
chemotherapy. Integration of immunotherapy into de-
finitive therapy schedules may present novel toxicities,
dosing schedules, and clinical trial design.
The first results from the GORTEC 2015–01 Pem-
broRad trial were reported at the American Society of
Clinical Oncology (ASCO) 2018 annual meeting
(NCT02707588). This trial tests the hypothesis that
combining checkpoint blockade with radiotherapy will
be superior to SOC cetuximab + radiotherapy in
locally-advanced HNSCC patients. With 25 versus 18
serious AEs in 94 and 78% of patients, preliminary
results show a manageable safety profile of pembroli-
zumab + radiotherapy compared to cetuxumab +
radiotherapy, respectively [153]. Expanding on the
previous trial, GORTEC 2017–01 (REACH) is testing
the possibility of synergy in combining avelumab +
cetuximab + radiotherapy versus SOC (cisplatin or
cetuximab + radiotherapy) in locally-advanced
HNSCC. To date, this trial has achieved an acceptable
safety profile and was granted approval to continue
by its Data and Safety Monitoring Committee [154].
Furthermore, results from RTOG-3504 were also re-
ported at ASCO 2018 regarding the combination of
nivolumab with platinum-based chemoradiation (CRT)
for patients with newly diagnosed intermediate/high-risk
(IR/HR) loco-regionally advanced HNSCC. This trial
evaluated the safety of adding PD-1 blockade to 4 stand-
ard radiotherapy regimens. Safety data for cohort 3
(cetuximab) were reported, finding the addition of nivo-
lumab to CRT to be safe. Specifically, 7/8 patients com-
pleted radiotherapy and 7/8 patients completed
cetuximab; 5 patients completed 10 concurrent doses of
nivolumab, 1 patient received 6 doses, 1 patient received
7 doses, and 1 patient was ongoing after 8 doses [152].
Additionally, JAVELIN head and neck 100
(NCT02952586), an ongoing phase 3 trial assessing ave-
lumab in combination with CRT for first-line treatment
of locally advanced HNSCC, will determine if CRT plus
PD-L1 blockade produces synergistic, superior anti-
tumor effects compared to SOC CRT in prolonging PFS
[157, 164]. Similarly, the phase 3 Keynote-412
(NCT03040999) follows positive preclinical and phase
1b data in investigating the use of pembrolizumab plus
CRT in patients with locally advanced HNSCC. Here
CRT is combined with a PD-1 inhibitor to determine if
immunomodulatory effects produced by CRT will en-
hance checkpoint blockade [165].
Consensus recommendations
The subcommittee recognizes the significant promise in
ongoing clinical trials regarding increasing response in
patients with HNSCC and providing durable, long-term
outcomes. The subcommittee notes that overall out-
comes in patients with HNSCC remain poor, and that
clinical trials involving immune checkpoint modulating
therapies are an excellent treatment option in most pa-
tients. As no combination strategies are currently ap-
proved in the IO-refractory disease setting, a majority of
the subcommittee (94%) recommends enrolling a patient
with R/M HNSCC into a clinical trial assessing a com-
bination immunotherapeutic approach. In this sense,
consensus was reached between all clinical members
of the subcommittee to recommend combination
therapy (notably chemotherapy + IO, once FDA-
approved) for rapidly growing disease due to the
need for an enhanced response rate. Additionally, in
identifying what tumor characteristics influence
treatment modality and sequence, the majority of the
subcommittee noted growth rate as being the most
important, however, many also noted the combined
importance of tumor volume and tumor size. Other
mentions of importance include existing immune
conditions, tumor site and patient symptoms.
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9. Quality of life and patient engagement
Many studies indicate significant quality of life improve-
ments in cancer patients being treated with immuno-
therapies compared to SOC. Quality of life issues
include pain, loss of cognitive ability, social ability deteri-
oration, and functionality to take part in a normal,
everyday life. Patients with HNSCC encounter many of
these issues, but also have other significant quality of life
issues to contend with including aesthetic considerations
and airway/vascular compromise due to tumor bulk.
The subcommittee discussed potential quality of life
issues pertaining to treatment with immunotherapies.
Literature review and analysis
CheckMate 141 assessed exploratory quality of life mea-
surements using the European Organization for
Research and Treatment of Cancer Quality of Life Ques-
tionnaire–Core 30 module (EORTC QLQ-C30), the
head-and-neck–specific module (QLQ-H&N35) and the
European Quality of Life–5 Dimensions (EQ-5D-3 L)
criteria. Scores for these modules range from 0 to 100,
with higher scores indicating better functioning or well-
being or higher symptom burden (although scales meas-
uring symptom burden were reverse-scored to facilitate
presentation). The proportion of patients reporting
health problems was assessed using the three-level ver-
sion of the EQ-5D-3 L questionnaire. Patients also com-
pleted the EQ-5D-3 L visual-analogue scale, for which
scores range from 0 to 100 and higher scores indicate
better perceived health status [43].
Assessments were obtained at the first two follow up
visits post-treatment (~ 35 days and ~ 80 days, respect-
ively). Patients who received nivolumab reported in-
creased quality of life improvement (> 10 points)
compared to patients who received chemotherapy. Eval-
uations noted that patients receiving nivolumab showed
improvement in social function, fatigue, and cognitive
ability. Nivolumab treatment also delayed time to clinical
deterioration compared to chemotherapy, including
delaying loss of sensory abilities, onset of pain, and diffi-
culty of social engagement [43]. Altogether, patient-
reported outcomes from CheckMate 141 revealed
stabilization or slight improvement in quality of life
measures such as social functioning and pain, while
SOC resulted in a clinically meaningful worsening across
many of the same measures [43].
Data on health-related quality of life (HRQoL) of pem-
brolizumab vs SOC for R/M HNSCC from the
KEYNOTE-040 clinical trial were presented at ASCO
2018. KEYNOTE-040 included a HRQoL analysis using
pre-specified questionnaires for all patients who received
at least one dose of pembrolizumab. The questionnaires
EORTC QLQ-C30, EORTC QLQ-H&N35, and EQ-5D
were given to patients at baseline, followed by weeks
three, six, nine, and every six weeks thereafter up to 12
months or termination of treatment and, finally, at a 30-
day post-treatment safety visit [166]. In this trial,
HRQoL was assessed by comparing the mean change
from baseline to week 15 and time to deterioration
(TTD) was defined as a ten point or greater decline from
baseline. At week 15, global health status (GHS)/QOL
scores remained stable for patients on pembrolizumab
(least-squares [LS] mean, 0.39; 95% CI: − 3.00–3.78) but
declined for those treated with SOC (LS mean − 5.86;
95% CI: − 9.68 – − 2.04), demonstrating a difference in
LS mean of 6.25 points (95% CI: 1.32–11.18; nominal 2-
sided p = 0.013) [166]. The largest variance from those
treated with pembrolizumab was seen in the patients
treated with docetaxel (LS mean - 10.23; 95% CI: 3.15–
17.30). Overall these data support previous reports of a
clinically meaningful benefit for patients treated with
pembrolizumab compared to SOC [166].
Consensus recommendations
Category 1 evidence from CheckMate 141 demonstrated
that while patients in the SOC group reported clinically
meaningful worsening of quality of life, as well as of
pain, sensory problems, and social-contact problems,
patients treated with nivolumab remained nearly stable
or showed slight improvements with significant p values
at both week 9 and week 15 for most comparisons [43].
Cancer patients are faced with an overwhelming
amount of information regarding treatment options. The
treating physician and staff have the opportunity and re-
sponsibility to provide adequate support and education
for the patient. 93% of the clinicians on the subcommit-
tee reported that they provide face-to-face counseling
with their patients in addition to providing literature to
educate patients on how immunotherapy works and its
associated toxicities. 53% of the subcommittee also rec-
ommends meeting with patients and their family mem-
bers during office visits to aid in information retention.
The subcommittee recommends that patients should
be provided with literature in the doctor’s office (or on-
line resources) to learn more fully about how immuno-
therapy works, what kinds of treatments and trials are
available, and what their experience of treatment might
be like, including toxicities. Clinical trials should be a
standard part of a doctor’s discussion with the patient
about their treatment options, especially for patients
whose disease has recurred after first-line therapy.
As for direct patient monitoring during and after treat-
ment, 47% of the subcommittee recommends having the
patient use an electronic system to manage daily levels
of pain, discomfort and depression. The subcommittee
believes an electronic system would lead to validated, re-
producible measures that would allow for a regular as-
sessment of response and toxicities and would allow the
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patient to record and manage symptoms and level of
discomfort. If using a patient scale specific for head and
neck cancers, the subcommittee (44%) recommends the
European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire (EORTC-HN35)
over other options.
With fewer high-grade side effects, treatment with
ICIs may provide stabilization or improvement in quality
of life compared to SOC. However, immunotherapy is
not without TRAEs that impact a patient’s quality of life
and need to be monitored. Overall, the subcommittee
was split as to which treatment management issues need
more attention, noting the effect of head and neck tu-
mors on nutrition and maintaining a patient’s quality of
life as the most important. The subcommittee stated that
basic health and nutrition are not to be neglected
throughout a patient’s treatment, especially when
HNSCC makes eating, drinking and breathing more
challenging, and patients often require specific support.
40% of the subcommittee agreed that quality of life
should be monitored every three months, and several
subcommittee members recommend patient quality of
life to be evaluated as often as the patient receives treat-
ment (27%). The majority of the subcommittee reported
treating depression in HNSCC patients with counseling
and selective serotonin reuptake inhibitors (SSRIs)
(57%). It was also suggested that doctors should pay
close attention to depression in general appointments
and should be sure to inquire into and monitor patients’
emotional well-being, specifically noting that it is easy to
develop depression with the stress and fear associated
with this diagnosis.
Conclusions
Currently, FDA-approved immunotherapies for head
and neck cancer patients include pembrolizumab with
platinum and fluorouracil (FU) for all patients and as a
single agent for patients whose tumors express PD-L1
CPS ≥1. Nivolumab and pembrolizumab are also ap-
proved for treatment in the platinum-failure setting for
R/M HNSCC patients [108, 109, 118]. As evidenced by
results of KEYNOTE-048, the field is currently focused
on earlier stages of disease, how to optimally combine
and sequence existing immunotherapies, as well as those
in development with conventional therapy (surgery, radi-
ation and chemotherapy).
Additionally, other challenges persist in bringing the
benefits of ICIs safely to a broader patient population.
Compared to AEs common to other therapies, irAEs
present with different symptoms and kinetics. Physicians
may experience considerable difficulty in not only recog-
nizing the signs and symptoms associated with a given
irAE, but also in obtaining accurate data on their inci-
dence and prevalence [107, 167]. irAEs unique to HNSCC
patients need to be identified and managed more readily
in order to balance immune toxicity with antitumor effi-
cacy. It will only be through continuous and improved en-
rollment in clinical trials that the medical and scientific
community will be able to generate the data required to
improve the care of patients with HNSCC. In this sense,
all patients should be considered for enrollment in
HNSCC trials whenever possible to do so.
Development of other immunotherapies and strategies
will be vital for continued progress in treating patients
with this heterogeneous disease. Increased understand-
ing of histology-specific considerations, potential bio-
markers, and further characterization of HPV- and EBV-
related cancers will also greatly assist in future thera-
peutic development, administration and management.
Similarly, overcoming challenges such as tumor immune
resistance, immune escape and immune-related adverse
events will be critical to advancing the field [168].
Importantly, with only a fraction of patients currently
benefitting from approved immunotherapies and a pau-
city of reliable patient selection markers, further identifi-
cation and understanding of such factors that predict
improved response and survival in patients with HNSCC
treated with immunotherapies is imperative. In develop-
ing a better understanding of immune checkpoint cellu-
lar processes and biomarker regulation, healthcare
professionals will be able to align the right patient more
precisely with the right drug, helping increase benefit
from these promising immunotherapies. Thus, due to
the distinct nature of immunotherapy, rapid progress in
the field, two ICIs now approved for use in HNSCC, and
one approved for cSCC in the head and neck area, clin-
ical guidance documents such as these are urgently
needed.
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